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Zusammenfassung 
 
Tumorwachstum ist ein mehrschrittiger und komplexer Vorgang, der ultimativ im 
Auswachsen von Metastasen endet. Da Metastasen für die Mehrheit der 
krebsbedingten Todesursachen verantwortlich sind, sind neue Ansätze um das 
Metastasieren von Krebszellen therapeutisch zu unterbinden unerlässlich. 
Voraussetzung für neue therapeutische Ansätze ist es, die zugrundeliegenden 
Mechanismen der Dissemination von Krebszellen vom Primärtumor an entfernt liegende 
Orte im Organismus zu verstehen. 
 
Asap1 (Arf-GAP with SH3-domains, Ankyrin-repeats and PH-domains) wurde in 
unserem Labor durch einen unvoreingenommenen Screen als prometastatisches Gen 
identifiziert. Es wurde dabei auch gezeigt, dass Asap1 funktionell zum Tumorwachstum 
in experimentellen Mausmodellen beiträgt und die Expression von Asap1 mit schlechter 
Prognose und verkürztem metastasenfreiem Überleben von Kolorektalkrebspatienten 
korreliert. 
 
Um die Rolle von Asap1 in normaler Physiologie und Krebs zu verstehen, habe ich in 
meiner Doktorarbeit Asap1 Knockout-Mäuse (Asap1GT/GT) untersucht, die durch gezielte 
Depletion des Asap1 Gens in unserem Labor generiert wurden.  Meine Untersuchungen 
ergaben, das Asap1GT/GT Mäuse bis ins Erwachsenenalter leben, obwohl es eine 
Reduktion der erwarteten Anzahl an homozygoten Knockout-Jungen gibt. Die 
Abwesenheit von Asap1 resultiert in Wachstumsverzögerung, in Atemnot und 
verminderter Angiogenese in überlebenden Jungen. Diese physiologischen 
Unterschiede sind transient und adulte Asap1 Knockout-Mäuse unterscheiden sich 
morphologisch nicht von Wildtyp-Mäusen. 
 
Zusätzlich habe ich die Rolle von Asap1 im Tumorwachstum und der Metastasierung in 
autochtonen Brustkrebsmodellen unter Verwendung von Asap1GT/GT Mäusen 
untersucht.  Meine Ergebnisse zeigen, dass der Verlust von Asap1 in MMTV-PyMT 
Mäusen zu einem früheren Beginn des Tumorwachstums, schnellerem 
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Tumorwachstums und mehr Lungenmetastasen führt.  Weiter habe ich die Effekte von 
Asap1 Defizienz auf das Verhalten von Brustkrebszellen und Fibroblasten, die von 
Asap1+/+ und Asap1GT/GT Mäusen isoliert wurden, untersucht. Zusammengefasst zeigen 
meine Ergebnisse, dass Asap1 ein wichtiger Regulator von Zellmotilität ist und der 
Verlust von Asap1 zu Entwicklungsdefekten in neugeborenen Mäusen führt. Weiter hat 
die Abwesenheit von ASAP1 Effekte, die sich nicht nur auf Tumorzellen beschränken, 
und führt zu einer erhöhten Anzahl an Metastasen im murinen MMTV-PyMT 
autochtonen Brustkrebsmodell. 
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Summary 
 
Tumor progression represents an array of complex events that ultimately lead to 
metastasis, the end-stage of cancer that is responsible for the majority of cancer-related 
mortalities. Improved ways to target the spread of cancer are thus imperative to treat 
cancer effectively. Understanding the mechanisms that regulate the dissemination of 
cancer cells from the primary site to distant places is a pre-requisite for such strategies.  
 
Asap1 (Arf-GAP with SH3-domains, Ankyrin-repeats and PH-domains) was identified by 
our lab in an unbiased screen to identify genes whose expression is associated with the 
metastatic phenotype. It was shown to be functionally involved in tumor progression in 
experimental animal models and this expression was correlated with poor metastasis-
free survival and prognosis in colorectal cancer patients.  
 
To understand the role of Asap1 in normal physiology and in cancer, in my thesis work I 
studied Asap1 knockout (Asap1GT/GT) mice, generated in our lab by targeted deletion of 
the gene. I observed that Asap1GT/GT mice can live to maturity, although there is a 
reduction in the expected number of homozygous knockout offspring at birth. Deletion of 
Asap1 results in growth retardation, respiratory distress and reduced angiogenesis in 
the surviving pups. This physiological phenotype in the absence of Asap1 is transient, 
and adult Asap1GT/GT mice are morphologically undistinguishable from the wild-type 
mice.  
 
I further studied breast tumor development and metastasis in Asap1GT/GT mice using 
autochthonous models of breast cancer. My results demonstrate that loss of Asap1 in 
MMTV-PyMT mice leads to an earlier tumor onset, faster tumor growth and increased 
metastasis to the lungs. I also examined the effect of ASAP1 deficiency on the 
behaviour of breast cancer cells and fibroblasts taken from Asap1+/+ and Asap1GT/GT 
mice. Taken together, my results show that Asap1 is a critical regulator of cellular 
motility and its absence gives rise to developmental defects in newborn mice. 
Deficiency of ASAP1 also has tumor cell non-autonomous effects, and leads to 
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increased numbers of metastases in the MMTV-PyMT autochthonous mouse model of 
breast cancer. 
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1. Introduction 
 
Cancer has been recognized to be a major health problem worldwide. Understanding 
the molecular basis of the complex mechanisms driving the process of cancer 
metastasis is crucial to build more potent therapeutic regimes to treat this disease. This 
study focuses on establishing and understanding the role of Asap1, a gene that has 
previously been correlated with metastasis of a wide variety of cancer types. The study 
describes the first reported attempt to understand the role of Asap1 in normal 
physiology and in a specific pathophysiological context, namely breast tumor metastasis 
in a murine model.  
 
1.1 Asap1: Discovery as a metastatic gene 
 
A transcriptomic screen using suppression subtractive hybridization (SSH) was 
performed by our lab that led to generation of metastasis-associated gene expression 
profiles for two rat adenocarcinoma models, namely rat mammary and pancreatic 
adenocarcinomas (Nestl et al., 2001). Pairs of clonal rodent tumor cell lines – one 
metastasizing and the other non-metastasizing, were used from both the rat tumor 
models. Subtractive libraries were generated when the transcripts from the non-
metastasizing tumor cell line were subtracted from those of the metastasizing cell line. 
Upon screening the two subtractive tumor libraries, 268 differentially expressed genes 
were identified. This approach led to several important outcomes, for example, it 
confirmed that the expression of previously known genes correlated with the metastatic 
phenotype, it associated already characterized genes that had not yet been linked with 
metastasis to the metastatic phenotype, and most importantly, it identified novel 
metastasis-exclusive genes.  
 
Subsequent to this screening, our lab performed a secondary screening on the panel of 
268 genes that were previously identified (Müller et al., 2010). In order to identify genes 
that may have a general function in tumor progression, the gene profile generated from 
metastatic mammary and pancreatic carcinoma was probed with cDNA derived from a 
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prostatic tumor progression model. By doing this, 68 genes were thus found to be 
upregulated in three different metastatic tumor models. They represented potential 
candidate genes that may be involved with tumor progression of many cancer types and 
Asap1 was one of these genes. Importantly, expression of ASAP1 is able to increase 
metastasis formation in experimental animal models (Müller et al., 2010), demonstrating 
a functional role for the protein in metastatic dissemination. Furthermore, its expression 
in colorectal cancer samples correlated with poor patient prognosis (Müller et al., 2010). 
 
1.1.1 Structure and function of ASAP1 
 
ASAP1 stands for Arf-GAP protein with SH3 domains, ankyrin repeats and pleckstrin 
homology domain. This reflects that fact that ASAP1 is a multi-domain protein that 
belongs to the Arf-GAP family. ADP-ribosylation factor (Arf) proteins are small GTPases 
that are involved in vesicle trafficking and modulating actin structures. The activity of Arf 
proteins is regulated by a class of proteins called Arf-GAPs, of which ASAP1 is a 
member. In addition, ASAP1 interacts with many different proteins through its various 
domains to bring about pleiotropic changes within the cell. The structure of ASAP1 and 
its splice variants is discussed here before the function of ASAP1 in various cellular 
processes and its association with many cancer types is described.  
 
1.1.1.1 Structure of ASAP1  
 
ASAP1 belongs to AZAP-family of Arf-GAPs that contains multiple domains, which 
dictate its subcellular localization and function. From the N-terminus, the sequence of its 
domains is a BAR (Bin–Amphiphysin–Rvs) domain, a PH (pleckstrin homology) domain, 
a zinc finger motif, a proline-rich region containing SH3 ligand motifs, eight repeats of 
the sequence (E/DLPPKP), and an SH3 domain at the C-terminus (Figure 1).  
 
The zinc finger motif is embedded within an evolutionary conserved Arf-GAP sequence, 
and is required for GAP activity. Sequence similarities are observed between the zinc 
finger motif found in ASAP1 and other proteins similar to ASAP1 that have a PH domain 
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at the N-terminus of the zinc finger and ankyrin repeats C-terminal to it. Together, the 
PH-Zinc finger-Ankyrin domains constitute the PZA module that is the minimal subunit 
of ASAP1 required for its GAP activity. This sequence is evolutionarily conserved, being 
also found in plants, worms and flies. The PH domain of ASAP1 contributes to 
phosphoinositide-dependent activation of ArfGAP domain and hence to regulation of 
Arfs. However, PIP2 binding to Arf is also important for the GAP activity of ASAP1, and 
hence phosphoinositide binds to both the enzyme, PZA, and the substrate, Arf, thus 
exhibiting dual roles in the regulation of Arf (Brown et al., 1998).   
 
BAR domains were first studied in the context of the mammalian proteins Bin and 
amphiphysin, and yeast proteins Rvs167 and Rvs161 (Lombardi and Riezman, 2001; 
Wigge and McMahon, 1998; Zhang and Zelhof, 2002). The BAR domain dimerizes to 
form a crescent-shaped structure that induces or detects membrane curvature and 
binds to acid phospholipids and other proteins (Farsad et al., 2001; Peter et al., 2004). 
The BAR domain of ASAP1 has been shown to be involved in the formation of transport 
intermediates, by mediating physical changes of the membranes of endocytic 
organelles and is also responsible for ASAP1-dependent regulation of cell spreading 
and EGFR recycling (Nie et al., 2006).  
 
ASAP1 also contains an SH3 binding domain through which it interacts with Src. This 
interaction likely affects the activity and localization of ASAP1 (Brown et al., 1998). 
ASAP1 contains a unique sequence repeat (E/DLPPKP) with proline rich regions that 
may facilitate homodimerization of ASAP1, as detected both in vitro and in vivo (Kam et 
al., 2000).  
 
Three known alternatively spliced variants of ASAP1 exist, namely, ASAP1a, ASAP1b 
(human) and rASAP1c (rat) (Brown et al., 1998; Müller et al., 2010). The two variants 
described in humans differ in their proline rich regions, in that ASAP1b lacks one of the 
three proline rich regions present in ASAP1a. The third splice variant, described in rat, 
lacks one of the three proline rich regions, like ASAP1b, and also a short sequence 
contained between the BAR domain and PH domain, that encodes 15 amino acid 
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residues. All three spliced variants retain the ArfGAP activity (Brown et al., 1998; Müller 
et al., 2010).  
 
 
Figure 1. Members of ASAP family of proteins. 
Schematic representation of structure, length and aliases of ASAP family members. Various 
domains like the BAR, PH, ArfGAP and proline-rich SH3 domains are shown for all the three 
members of ASAP family. Previously used nomenclature for each of the member is given. 
 
 
ASAP1 is closely related to other members of the ASAP family (Figure 1). ASAP2 also 
has PIP2-dependent GAP activity (Andreev et al., 1999) and acts as an adapter protein 
that recruits many endocytic proteins to site of Arf6 activation (Hashimoto et al., 2005). 
ASAP3 lacks the SH3 domain at the C-terminus, unlike ASAP1 and ASAP2. Like 
ASAP1, ASAP3 is associated with focal adhesions (FAs) and central dorsal ruffles 
(CDRs), but is not required for invadopodia formation (Ha et al., 2008). This shows 
independent functions for different ASAP family members despite a common 
localization.  
 5 
1.1.1.2 Cellular functions of ASAP1 
 
The most intensively studied function of ASAP1 is its role as an Arf-GAP. I will therefore 
describe the function of Arf-GAP proteins in general as well as the specific Arf-GAP 
functions of ASAP1, before considering other functions of ASAP1. 
 
1.1.2 The Ras superfamily of small GTPases 
 
Small GTPases are regulatory proteins that participate in cellular signaling by acting as 
‘molecular switches’ that begin their function when guanine nucleotide exchange factors 
(GEFs) facilitate GTP binding on them and terminate their function when GTPase 
activating proteins (GAPs) dissociate the bound GTP by hydrolyzing it. Small GTPases 
are enzymes that bring about a wide range of cellular processes (Wennerberg et al., 
2005). The Ras superfamily of small guanosine triphosphatases (GTPases) 
encompasses more than 150 proteins distributed across five major groups. These 
protein families are classified on the basis of their sequences and function. Due to lack 
of functional data, a definitive classification of these proteins has not been possible yet. 
The biochemical mechanism of action is common across these sub-families, and that is, 
all of these small GTPases act as binary molecular switches (Vetter and Wittinghofer, 
2001). All of these proteins also share a highly conserved ~ 20 kDa of GTP/GDP-
binding sequence, the G box located at their N-terminus. Small GTPases have high 
affinity for GDP/GTP binding, but they do not have the ability to hydrolyze GTP or 
exchange GDP for GTP. For this, they depend on other regulatory proteins called 
guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). 
Each of the classified group within the Ras superfamily uses distinct set of GEFs and 
GAPs. As outlined (Figure 2), the five groups of proteins that make up the Ras 
superfamily of GTPases are the Ras, Rho, Rab, Ran and Arf families.  
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Figure 2. The Ras superfamily of GTPases. 
The five major groups – Ras, Rho, Rab, Ran and Arf – that comprise the Ras superfamily of 
GTPases are shown schematically. Examples of members of each family is given. Arf family is 
highlighted, and is discussed in the following sections. 
 
 
1.1.3 The Arf family of GTPases 
 
The ADP-ribosylation factor family represents a class of myristoylated, low molecular 
weight, guanine nucleotide binding (G) proteins (D’Souza-Schorey and Chavrier, 2006). 
These proteins are important regulators of organelle structure and modulate actin 
structures. They also participate in vesicle trafficking by recruiting coat proteins that 
facilitate sorting of cargo into vesicles. There exist three classes into which the six 
mammalian Arf GTPases have been categorized. ARF1, ARF2 and ARF3 belong to 
Class I; ARF3 and ARF4 to Class II and ARF6 represents Class III. Apart from these, 
more than 20 ARF-like (ARFL) proteins exist that perform more pleiotropic roles than 
ARFs (Gillingham and Munro, 2007). As mentioned earlier, there are two classes of 
regulatory proteins that enable ARFs to function. These are ARF GEFs and ARF GAPs. 
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ARF GAPs regulate ARFs in a spatio-temporal manner, in that they undergo 
conformational changes upon GTP-binding. Arf-GAP proteins remain in close proximity 
to membranes owing to an amphipathic helix at their N-terminus that allow them to dock 
into the membrane, as well as through the lipid modification in which myristoyl groups 
are added either co- or post-translationally that help recruit Arf-GAPs to the 
membranes. Although ARF1 and ARF3 are released from the membrane upon GTP 
hydrolysis, ARF4 and ARF5 have been found to remain attached to ER-Golgi 
intermediate compartment (ERGIC) membrane in their GDP-bound conformation (Chun 
et al., 2008). ARF6 appears to be bound to membranes as well (Duijsings et al., 2009). 
The literature suggests that the nucleotide state of these membrane bound ARFs may 
dictate various cellular signaling pathways.  
 
1.1.4 Arf-GTPase activating proteins: Arf-GAP domains 
 
The Arf-GAP domain was first identified in rat as the domain responsible for induction of 
GTP hydrolysis on Arf1 (Cukierman et al., 1995). The Arf-GAP domains are highly 
conserved and exist in the earliest eukaryotes. In the yeast Saccharomyces cerevisiae 
at least five Arf-GAPs have been identified while the mammalian Arf-GAPs have been 
shown to range from small proteins to large multi-domain proteins functioning as 
scaffolds for cellular signaling. Over a period of about a decade, scientists have agreed 
upon the following nomenclature for human Arf-GAP domain containing proteins. The 
31 human genes that encode proteins containing the Arf-GAP domain have been 
divided into 10 subfamilies (Figure 3). This classification is based on sequence 
similarities and the conservation of domain architecture within each subfamily (Kahn et 
al., 2008).  
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Figure 3. Human Arf-GAPs. 
Schematic outline of the 31 genes in humans that encode Arf-GAPs, as classified into ten 
families. The chromosomal location of each gene is shown. ASAP1, belonging to the ASAP 
family, is highlighted. 
 
 
1.1.5 Role of ASAP1 Arf-GAP domain in the regulation of cell motility 
 
GAP activity of ASAP1 is stimulated specifically by the signaling lipid 
phosphatidylinositol 4,5- bisphospate (PIP2) (Brown et al., 1998). PIP2 binds to PH 
domain of ASAP1, which can serve to both recruit ASAP1 to a membrane surface and 
to induce an activating conformational change in the protein (Che et al., 2005). Ectopic 
ASAP1 enhances cell migration toward platelet-derived growth factor (PDGF) and 
Insulin-like growth factor-1 (IGF-1). This chemotactic effect appears to result from a 
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general increase in cell motility, as ASAP1-expressing cells also exhibit enhanced basal 
and chemokinetic motility. The increase in cell motility is dependent on GAP activity. 
Inhibition of cell spreading by ASAP1 is not GAP-dependent, indicating that spreading 
and motility are altered by ASAP1 through different pathways. A possible model for 
general enhancement of cell motility by ASAP1 could depend on the ability of ASAP1 to 
destabilize focal adhesions. Such a destabilization could lead to an increase in basal, 
chemokinetic and chemotactic migration rates. Focal adhesion disruption has been 
documented in transiently transfected ASAP1 NIH3T3 cells. The ability of ASAP1 to 
increase cell motility in a GAP-dependent manner suggests this effect is mediated by 
deactivation of the ASAP1 substrate Arf1. Interestingly, Arf1 and Arf6 appear to function 
antagonistically, with Arf1 activation being anti-migratory and Arf6 activation being pro-
migratory (Furman et al., 2002). In contrast, overexpression of ASAP1 inhibits the 
formation of PDGF-induced membrane ruffles in a GAP dependent manner (Randazzo 
et al., 2000).  
 
1.1.5.1 Other functions of ASAP1 domains 
 
ASAP1 serves as an important regulator of a wide variety of physiological events 
occurring within a cell (Figure 4). ASAP1 binds to proteins that function as part of the 
endocytic machinery, such as CIN85, POB1 and amphiphysin IIm (Hashimoto et al., 
2004; Kowanetz et al., 2004). CD2AP, a protein highly related to CIN85, binds to 
ASAP1 and recruits it to the plasma membrane (Liu et al., 2005). The SH3 domain of 
ASAP1 mediates binding to POB1, and POB1 simultaneously binds to the Ral binding 
protein, RalBP. Together, the ASAP1-POB1-RalBP complex regulates actin remodeling 
by controlling RhoGTP levels, thereby coordinating changes in the actin cytoskeleton 
with membrane trafficking. This is also important for maintenance of invadopodia (Ikeda 
et al., 2001; Oshiro et al., 2002). 
 
ASAP1 binds to several protein kinases, including c-Src, focal adhesion kinase (FAK), 
and the FAK homologue Pyk2 (Brown et al., 1998; Liu et al., 2002). Src phosphorylates 
ASAP1 and this is required for the formation of invadopodia and podosomes. These are 
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actin rich adhesion structures on the ventral surface of cells that mediate adhesion, 
extra-cellular matrix (ECM) degradation and tumor invasion. Src and Pyk2 directly 
phosphorylate ASAP1 and this inhibits GAP activity for Arf1 (Kruljac-Letunic et al., 
2003).  
 
Crk and CrkL are adapter proteins that bind to ASAP1 (Oda et al., 2003). CrkL binds to 
paxillin and ASAP1 binding to Crk and CrkL is necessary for the association of ASAP1 
with focal adhesions.  
 
Cortactin is a multi-domain protein that is found in peripheral membrane ruffles and 
invadopodia. ASAP1 and cortactin associate with invadopodia in invasive breast cancer 
cell lines (Onodera et al., 2005). ASAP1 and cortactin have been proposed to be a part 
of the invasive machinery in cancer cells. This complex links the highly tubulated 
membranes found in invadopodia and podosomes to polymerized and branched actin 
(Randazzo et al., 2007). ASAP1 may function as a regulated signaling platform to 
control the dynamics of invadopodia and podosomes. These structures are labyrinths of 
tubulated membranes associated with polymerized actin (Buccione et al., 2004). The 
BAR, PH and Arf-GAP domains of ASAP1 bind to Arf-GTP to induce membrane 
tubulation, hence ASAP1 could be considered as an Arf effector (Nie et al., 2006). 
ASAP1 must be phosphorylated by Src to function at podosomes. Therefore, ASAP1 
integrates three signals – those from Arf-GTP, PIP2 and Src.  
 
ASAP1 associates with CDRs (Randazzo et al., 2000). CDRs are induced by growth 
factors like platelet-derived growth factor (PDGF).  These structures are rings of 
dynamic remodeling, polymerized actin at the dorsal surface of cells associated with 
plasma membranes undergoing extensive endocytosis. The BAR domain of ASAP1 
contributes to the formation of tubules from synthetic large unilamellar vesicles in vitro 
and Arf contributes to this ASAP1-mediated tubulation. Therefore, the membrane 
curvature-inducing function of ASAP1 is coupled with Arf signaling (Nie et al., 2006).  
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The Rab11-family interacting protein 3 (FIP3) was found to stimulate the GAP activity of 
ASAP1. It was found to directly interact with the BAR domain of ASAP1. ASAP1 
participates in transferrin trafficking through a Rab11-dependent pathway (Inoue et al., 
2008). Ablation of ASAP1 abolishes ciliary targeting and causes formation of actin rich, 
periciliary membrane projections that accumulate mislocalized rhodopsin. ASAP1 
serves as a scaffold that brings together the proteins necessary for transport of the cilia 
including GTP binding protein Arf4 and the G protein of Rab family Rab11 and Rab8, 
linked by the Rab 8 exchange factor, Rabin 8 (Wang et al., 2012). 
 
 
 
 
Figure 4. Pleiotropic functions of ASAP1 in the cell. 
ASAP1 is involved in regulating a wide variety of cellular processes. ASAP1 is able to bind to 
many different proteins to form complexes and thus bring about cellular functions. Shown here 
are its interaction partners that are implicated in membrane recruitment (in yellow boxes); 
ASAP1 may influence cytoskeletal remodeling (green boxes); it is a known functional 
component of invadopodia (orange boxes); ASAP1 binds proteins that are part of endocytic 
machinery (blue boxes); ASAP1 regulates membrane trafficking (purple boxes) and ASAP1 
associates with CDRs (light blue box). 
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ASAP1 overexpression inhibits cell spreading and alters paxillin localization to focal 
adhesions (Liu et al., 2002). Mislocalization or reduced expression of ASAP1 inhibits 
cell spreading and migration by influencing Arf1-GTPase cycling. CD2AP stably 
associates with ASAP1. Mislocalization of ASAP1 to mitochondria with a CD2AP mito 
fusion protein inhibits fibronectin-mediated cell spreading and migration. siRNA 
mediated ASAP1 reduction retards cell spreading and inhibits cell migration. 
Mislocalization or siRNA mediated reduction of ASAP1 causes an increase in 
intracellular Arf1-GTP and loss of paxillin from cell adhesions. Given previous findings, it 
was concluded that ASAP1 contributes the process of adhesion assembly by regulating 
dynamic GTP/GDP cycling of Arf1-GTPase (Liu et al., 2005). CD2AP localizes to 
membrane ruffles and therefore the interaction of CD2AP with ASAP1 provides a 
possible mechanism by which ASAP1 localization on the plasma membrane is further 
refined upon growth factor receptor engagement. Abrogation of ASAP1 function with 
different approaches caused similar phenotypes to those observed with ASAP1 
overexpression, suggesting an important role for the dynamic cycling of Arf1-GTPase in 
adhesion assembly rather than its active GTP-bound form. Depletion of ASAP1 leads to 
inhibition of common pathways that partially compensate for the motility defects induced 
by the loss of ASAP1 function. It is possible that other compensatory Arf-GAPs are 
exploited by growth factors under ASAP1 depleted conditions (Liu et al., 2005).  
 
The importance of the SH3 domain of ASAP1 in promoting metastasis has been 
highlighted by mutational analysis in our lab that suggests that binding to SH3 domain-
containing proteins, such as SLK (Ste-20-like kinase), is essential for ASAP1 to promote 
metastasis. SLK was shown to co-immunoprecipitate with ASAP1b and ASAP1c and 
thus interactions through SH3 domain of ASAP1 may be functionally involved in 
regulating metastasis (Müller et al., 2010).  
 
Previous work from our group has implicated ASAP1 in the process of metastasis (Nestl 
et al., 2001; Müller et al., 2010), and ASAP1 expression has been associated with a 
wide variety of cancer types. My thesis work the involvement of ASAP1 in cancer, and 
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specifically breast cancer metastasis. In the next section I therefore present the basics 
of breast cancer and current models and evolving paradigms in the field of metastasis.  
 
1.2 Breast cancer: our knowledge from the bed and the bench 
 
Breast cancer comprises a group of heterogeneous diseases that develops as a local 
lesion but has the potential to metastasize to various sites in the body (Weigelt et al., 
2005). It is the most common malignant disease affecting women worldwide, and it is 
estimated that over 508,000 women died of this disease in 2011 (Global health 
estimates, WHO, 2013). In 2012, the estimated annual incidence of breast cancer in 40 
European countries was found to be 94.2/100,000 and the mortality to be 23.1/100,000 
(Ferlay et al., 2013). In most of the Western countries the mortality rate has decreased, 
owing to better treatment outcomes and earlier detection. In European women, 
however, breast cancer remains the leading cause of cancer-related deaths (Allemani et 
al., 2015; Autier et al., 2010).  
 
1.2.1 Clinical features of breast cancer  
 
The diagnosis of breast cancer is made on the basis of imaging and clinical assessment 
that includes bilateral mammography and ultrasound of the breast and regional lymph 
nodes and palpation of the breast and locoregional lymph nodes. Apart from rendering 
prognostic value, pathological assessment of the primary tumor also leads to pre-
treatment disease evaluation. Physical attributes like tumor size, histological 
examination of the tumor and lymph node involvement contribute to the tumor-node-
metastasis (TNM) staging system of breast cancer. This system addresses the 
histological type, grade and immunohistochemical (IHC) evaluation of hormone receptor 
status (estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor 2 receptor (HER2)). Based on tumor histology (Table 1.1), breast tumors 
are stratified into several subtypes  (Senkus et al., 2015).  
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Breast cancer represents a heterogeneous group of malignancies originating from the 
ductal epithelium. The mammary epithelium is bilayered, with a central luminal epithelial 
cell layer surrounded by an outer myoepithelial cell layer and basement membrane 
(Nelson and Bissell, 2006). Using traditional histological approaches, three subtypes of 
breast tumors with different biological behavior have been identified - luminal and basal 
breast tumors that resemble the luminal and basal breast epithelium, and the HER2-
positive breast tumors that overexpress HER2 but lack ER and PR (Kittaneh and Glück, 
2011). However, patients with breast cancer of the same stage can differ significantly in 
their disease outcomes and therapy responses because the strictly clinical predictors 
may fail to accurately classify the breast tumors. To address this, considerable research 
has been performed in recent years to better stratify breast cancer patients into more 
meaningful breast cancer subtypes (Kittaneh et al., 2013; van ’t Veer et al., 2002).  
 
1.2.2 Gene profiling of breast tumors 
 
As a novel approach to predicting prognosis in breast cancer patients, the expression 
pattern of a panel of specific tumor-related genes has been studied. The specific gene 
expression patterns have the ability to identify tumors with more aggressive biology and 
thus can help with precise and more accurate quantification of prediction of recurrence 
as compared to traditional clinical methods (Kittaneh et al., 2013). The genetic paradigm 
has led to two important outcomes – it has been possible to identify new intrinsic 
subtypes of breast cancer, and predictive genomic signatures have been established for 
breast cancer.  
 
1.2.2.1 Identification of new intrinsic breast cancer subtypes 
 
An integrated approach to profile breast cancers into different subtypes utilizing 
information from both the clinical features and gene expression signatures has enabled 
identification of at least 7 different biologic subtypes of breast cancer (Kittaneh and 
Glück, 2011; Sørlie et al., 2001, Table 1).  
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Luminal-like breast cancer 
This subtype has a gene expression profile similar to the normal luminal breast 
epithelium. Luminal A breast tumors comprise about 40% of all breast cancers and 
correlate with a favorable prognosis. This subtype has been shown to overexpress ER-
regulated genes and under expression of the HER2 gene cluster (Hu et al., 2006; 
Kennecke et al., 2010). Luminal B breast tumors represent about 20% of breast cancers 
and are associated with a higher risk of relapse and poor prognosis. These tumors have 
lower ER-related genes and varying expression of the HER2 gene cluster (Voduc et al., 
2010). A third subtype, namely Luminal C has been found with high expression of a set 
of genes with presently no known functions (Sørlie et al., 2001).   
 
HER2 enriched breast cancer 
Comprising about 20-30% of all breast cancers, this subtype is characterized by high 
expression of the HER2 cluster of genes and low expression of the luminal cluster 
genes that include cytokeratins (CKs) CK7, CK8, CK18 and CK19. This breast cancer 
subtype has poorer prognosis as compared to Luminal A breast cancer (Sørlie et al., 
2003).   
 
Basal-like breast cancer  
This breast cancer subtype derives its name from the shared gene expression pattern 
with normal basal epithelial cells and represents about 15% of the invasive ductal breast 
cancers. Owing to a low expression of luminal and HER2 gene clusters, this breast 
cancer subtype is often considered ‘triple negative’. However the term is not 
synonymous with basal-like breast cancer (Kennecke et al., 2010).   
 
Claudin-low breast cancer 
This subtype is characterized by low expression of luminal differentiation markers and 
high expression of genes involved in cell migration, differentiation, angiogenesis and 
immune-related genes. Histologically, this breast cancer subtype is negative for 
hormone receptor and HER2 expression and often part of the basal intrinsic subtype 
(Prat et al., 2010).   
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Normal breast-like breast cancer 
Genes expressed in this subtype of breast cancer are similar to those expressed by 
adipose tissue and other nonepithelial cell types. These tumors exhibit low expression 
of luminal epithelial genes and a high expression of basal epithelial genes (Sørlie et al., 
2001).  
 
Breast Cancer Subtype 
Clinicopathologic Surrogate 
ER PR HER2 
Luminal A 'Luminal A-like’ + high - 
Luminal B      
		 'Luminal B-like HER2-negative’ + low - 
		 'Luminal B-like HER2-positive’ + high/low + 
Luminal C*     
HER2 overexpression ‘HER2-positive (non-luminal)’ - - + 
Basal-like ‘Triple-negative (ductal)’ - - - 
Claudin-low*  - - - 
Normal breast-like*         
 
Table 1. Breast cancer subtypes and their clinicopathologic surrogate markers. 
*Recently identified breast cancer subtypes. 
 
 
1.2.3 The role of the microenvironment in breast cancer progression  
 
Tumor growth does not just rely on the growth of malignant cells, but also on the various 
stromal cells found in the surrounding environment of the primary tumor. It has been 
well established that a tumor cell begins its growth as a neoplastic lesion, most often in 
epithelial cells, and is contained within a defined boundary of basement membrane 
(BM). The cells adjacent to this growing lesion, namely the immune cells, blood vessels 
and fibroblasts, together with the extracellular matrix (ECM) and BM that surround the 
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lesion, constitute the stroma (Hanahan and Weinberg, 2000; Rønnov-Jessen et al., 
1996). In the case of the breast, the epithelium is embedded within the mammary 
stroma that accounts for 80% of the breast volume and is formed by adipose tissue, 
interstitial connective tissue and blood vessels (Nelson and Bissell, 2006).   
 
Tumor cells from the primary tumor detach and enter the vasculature as circulating 
tumor cells (CTCs) that can be transported to distant secondary sites as disseminated 
tumor cells (DTCs) that may then form metastatic tumors (Sleeman et al., 2011). 
Distinct microenvironments function at each step of this process and thus regulate 
disease progression.  
 
1.2.3.1 Stromal regulation of the primary tumor 
 
A neoplastic lesion embedded within the epithelium, and contained by a defined BM, is 
termed carcinoma in situ (CIS). The surrounding stroma of CIS is called ‘reactive 
stroma’. Studies indicate a bidirectional influence of CIS and the reactive stroma on 
each other, mediated through the BM barrier (Rønnov-Jessen et al., 1996). Whereas a 
normal stroma contains a certain number of fibroblasts, the reactive stroma maintains a 
higher number of fibroblasts, increased capillary density and type-I collagen. 
Experiments on cancer-prone chickens show that the reactive stroma promotes 
tumorigenesis through oncogenic signals (Sieweke et al., 1990). 
 
The stromal components that have been implicated in promoting primary tumor growth 
include endothelial cells that are a part of the lymphatic and blood circulatory system, 
pericytes, fibroblasts and many bone marrow-derived cells (BMDCs) such as 
macrophages, neutrophils, mast cells, myeloid cell-derived suppressor cells (MDSCs) 
and mesenchymal stem cells (MSCs) (Sleeman and Cremers, 2007).  
 
Fibroblasts form a very prominent part of the tumor-stromal compartment. Normal 
mammalian fibroblasts are a heterogeneous cell population that are widely distributed 
and identified by their characteristic elongated, spindle-shaped morphology (Tarin and 
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Croft, 1969). The physiological roles of fibroblasts include regulation of ECM by 
contributing to ECM deposition and also secretion of matrix-degrading enzymes like 
matrix metalloproteinases (MMPs) (Simian et al., 2001; Tomasek et al., 2002). During 
wound repair, fibroblasts invade the lesion and generate ECM that acts as a scaffold for 
various cell types, thereby mediating scar formation and tissue fibrosis. Fibroblasts 
possess cytoskeletal elements that promote contractions of the healing wound. It has 
been observed that fibroblasts isolated from a fibrotic tissue or a tissue undergoing 
wound healing, are ‘activated’ and proliferate and secrete higher levels of ECM 
constituents than those fibroblasts isolated from healthy organs. Once the process of 
wound healing is completed, the number of such ‘activated’ fibroblasts decreases, thus 
restoring the resting cell phenotype (Tomasek et al., 2002). Tumors have previously 
been described as wounds that do not heal, and hence cells that have roles in injury-
response, such as fibroblasts are important and are involved with cancer initiation and 
progression (Dvorak, 1986; Kalluri and Zeisberg, 2006).  ‘Activated’ fibroblasts within 
the tumor stroma are called cancer associated fibroblasts (CAFs). In breast cancer, 
80% of stromal fibroblasts acquire the activated phenotype (Sappino et al., 1988, Figure 
5).  
 
Tumor stroma forms most of the tumor mass, and the growth of the stroma is supported 
by the tumor cells in that tumor cells secrete pro-fibrotic growth factors that promote 
growth and activation of stromal fibroblasts (Elenbaas et al., 2001). Overexpression of 
transforming growth factor ß (TGFß) in pancreatic cancer corresponds to a fibrotic 
response, although it is unclear whether the fibrotic response is a wound-healing 
mechanism by CAFs to repair the lesion or TGFß stimulates the accumulation of CAFs 
(Lohr can res 2001). PDGF is secreted by tumor cells, and although tumor cells do not 
express PDGF receptors, it has been shown that this growth factor exerts its effects via 
paracrine signaling that involves fibroblasts and endothelial cells (Forsberg et al., 1993). 
Another growth factor, basic fibroblast growth factor 2 (bFGF2) has been demonstrated 
to induce proliferation in 3T3 fibroblasts, involvement in tissue fibrosis and induction of 
angiogenesis (Folkman et al., 1988; Strutz et al., 2000).  
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To support growth and development of the tumor at early stages, an important step is 
the induction of angiogenesis (Folkman, 1971). While tumor cells are able to secrete 
VEGF, it is the stromal components – specifically, fibroblasts and inflammatory cells, 
that provide the bulk of VEGF required for tumor angiogenesis (Fukumura et al., 1998).  
 
 
 
Figure 5. Interactions of activated fibroblasts in tumor stroma. 
Various communications of activated fibroblasts with cancer cells, stromal epithelial cells, 
endothelial cells and pericytes, facilitated by growth factors and chemokines (Zeisberg and 
Kalluri, 2006). 
 
Progression of cancer to metastasis is a systemic disease process. Cells from the 
primary tumor invade the local tissue. In the process of intravasation, they enter 
capillaries, from where they are taken to distant sites. The circulating tumor cells (CTCs) 
exit the circulatory system in a process known as extravasation and enter the secondary 
sites. At each of these steps of the invasion-metastasis cascade, key events like 
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Invasive carcinoma
TGFβ
TGFβ
HGF
Tenascin C
Collagen I, III
MCP1
VEGF
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IL-1
Inflammatory cells
Pericyte
Mesenchymal cells that wrap 
around endothelial cells in 
microvessels. They share the 
common basement membrane 
with the vascular endothelial 
cells.
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Fibroblast-like cells in the liver 
that express glial fibrillary 
acidic protein and nestin, and 
are thought to be neural-crest-
derived.
escape the primary tumour site. MMPs and other pro-
teases also directly affect the motility and invasiveness of 
cancer cells. Such a direct effect has been elucidated for 
MMP3 (also known as stromelysin 1), which is highly 
expressed in fibroblasts. MMP3 directly cleaves the extra-
cellular domain of E-cadherin, prompting normal mam-
mary epithelial cells to disaggregate and undergo EMT, 
promoting cancer-cell invasiveness88. MMP1 also shows 
such a tumour-promoting effect. The protease-activated 
receptor PAR1, which is a tethered-ligand receptor, is acti-
vated by proteolytic cleavage of the extracellular domain 
by MMP1, promoting cancer cell migration and invasion 
through PAR1-dependent Ca2+ signals85.
The role of CAFs in metastasis
Some studies have indicated that activated fibroblasts at 
the metastatic site promote the proliferation of cancer cells 
there and, similar to the CAFs in the primary tumour, are 
conducive to tumour growth89. Such metastasis-associated 
fibroblasts could represent a variant of CAFs. Hepatic 
metastasis following the injection of B16M melanoma 
cells in mice89 showed that the formation of liver metas-
tases is associated with the activation of stellate cells even 
before the tumour reached a diameter of 150 µm (REF. 89). 
This supports the notion that activated stellate cells might 
be important in creating a niche for the cancer cells and 
supporting the initiation of angiogenesis90. A different 
study systematically evaluated the effect of fibroblasts 
on the proliferation of melanoma cells and found that 
only the melanoma cells that metastasized were influ-
enced by fibroblasts91. This indicates that specific stimuli 
(which are not yet known) provided by fibroblasts create 
a niche that promotes the growth of subsets of cancer 
cells at distant sites. Tumour growth and metastasis in 
FSP1-deficient mice (FSP1-deficient fibroblasts show 
decreased motility) is significantly reduced92. Injection 
of wild-type fibroblasts into these mice partially reversed 
the observed phenotype, providing further evidence for 
the involvement of metastasis-associated fibroblasts in the 
emergence of metastasis92.
Fibroblasts and TGFβ
As discussed above, EMT involving cancer cells is con-
sidered an important determinant of cancer progres-
sion, as it facilitates tumour invasion and metastasis68. 
Various exogenous stimuli control EMT of cancer cells68. 
These include MMPs, integrins and members of the 
TGFβ superfamily of proteins, which are growth factors 
that bind to tyrosine-kinase receptors, such as epider-
mal growth factor (EGF) and FGF2. Downstream of 
tyrosine-kinase receptors, complex signalling networks 
mediate the induction of EMT. Most of the exogenous 
EMT stimuli are potentially contributed by CAFs10,93 
(FIG. 3). Therefore, it is conceivable that CAFs have an 
important role in mediating EMT of carcinoma cells, 
thereby contributing to the progression of cancer.
As mentioned above, TGFβ has a role in the recruit-
ment of fibroblasts. However, TGFβ is also the most 
prominent of the factors within the tumour micro-
environment that are known to induce EMT of cancer 
cells94. Before the initiation of cancer, and during the early 
stages of carcinogenesis, TGFβ probably functions as a 
tumour suppressor. By contrast, during advanced stages 
of cancer, TGFβ signalling promotes cancer progression 
and metastasis60. Although the underlying molecular 
mechanisms are not fully understood, it is becoming 
increasingly clear that the dual effect of TGFβ on dif-
ferent signalling pathways, and by extension the effect of 
CAFs, needs consideration33,95.
In normal tissues, the anti-proliferative and pro-
apoptotic response of epithelial cells to TGFβ might limit 
the growth of normal epithelium and the emergence of 
malignant carcinomas22,94. With regard to fibroblasts, 
TGFβ facilitates fibroblast–epithelial-cell interactions, 
which further suppress cancer initiation93. In advanced 
cancer, on the other hand, the anti-proliferative effect of 
TGFβ is progressively lost — instead, it facilitates EMT 
of cancer cells, potentially promoting invasiveness and 
metastasis94. Signalling pathways that are implicated 
in TGFβ-mediated EMT involve Smad signalling, the 
phosphatidylinositol-3-kinase–Akt pathway and signal-
ling through RHOA and p38 MAPK69,96 (FIG. 4). However, 
several studies indicate that TGFβ signalling involving 
Smads, and SMAD3 in particular, is the principal deter-
minant of EMT, whereas the other pathways function 
synergistically but are dispensable94.
Figure 3 | Functions of activated fibroblasts in the tumour stroma. Fibroblasts 
communicate with cancer cells, resident epithelial cells, endothelial cells, pericytes and 
inflammatory cells through the secret on of growth factors and chemokines. Through the 
increased deposition of collagen typ s I and III nd de novo expr ssion of tenascin C they 
induce an altered extracellular-matrix microenvironment, which potentially provides 
additional oncogenic signals, probably leading to accelerated cancer progression. 
Fibroblasts mediate the inflammatory response by secreting chemokines such as 
monocyte chemotactic protein 1 (MCP1) and interleukins such as IL-1. Fibroblasts 
interact with the microvasculature by secreting matrix metalloproteinases (MMPs) and 
vascular endothelial growth factor (VEGF). Fibroblasts also provide potentially oncogenic 
signals such as transforming growth factor-β (TGFβ) and hepatocyte growth factor (HGF) 
to resident epithelia, and directly stimulate cancer-cell proliferation and invasion by 
secreting growth factors such as TGFβ and stromal-cell-derived factor 1 (SDF1). 
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changes in cell adhesive properties and acquisition of motile phenotypes by the tumor 
cells, occur (Sleeman, 2000). Cellular motility is central to the spread of cancer cells as 
it helps in local invasion of connective tissues, lymphatic system and the vasculature 
(Wang et al., 2005).  
 
1.2.3.2 Local invasion and intravasation: cellular structures enabling motility 
 
Cellular motility is of paramount importance in physiological events such as 
development and immune responses, as well as in many pathological events, like 
cancer metastasis and cardiovascular diseases (Parsons et al., 2010). The movement 
for most cells begins when the cell membrane protrudes to form adhesion structures 
that connect the actin filaments at the leading edge of the cell to the substratum, and 
the cell moves forward along the actin while the rear end of the cell disengages 
adhesions (Parsons et al., 2010; Sheetz, 1999). Cells of a tumor detach by remodeling 
their actin cytoskeleton, they are able to invade ECM and migrate into the bloodstream 
to be transported to secondary sites following extravasation (Talmadge and Fidler, 
2010). Cellular motility is a key process that facilitates these steps of the invasion-
metastasis cascade. Distinct, organized adhesive structures mediate interactions 
between cellular cytoskeleton and ECM.  
 
The cell membrane of a migratory cell is capable of undergoing extensive reshaping to 
fulfill specific physiological requirements (Buccione et al., 2004). Morphologically and 
functionally distinct structures are formed by invagination or protrusion of cell 
membranes. These structures are called lamellipodia, filopodia and the phagocytic cup. 
The formation of these cellular processes is dependent upon the assembly of 
filamentous- (F)-actin and its associated proteins. In order to form these surface-
specialized structures, a certain network of proteins is needed, and often includes F-
actin, Arp2/3 complex, N-WASP (neural-Wiskott Aldrich syndrome protein), along with 
Rho family of GTPases (Linder and Aepfelbacher, 2003). Based on this protein network 
that constitutes the actin-based machinery, a cell may distort membranes transiently 
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and form different membrane structures like podosomes, invadopodia and circular 
dorsal ruffles (Buccione et al., 2004).  
 
Podosomes are found on the ventral side of cells like osteoclasts, macrophages and 
endothelial cells and are utilized to degrade ECM. Podosomes in osteoclasts arrange 
themselves in such a way to form a rosette, that is a compartment in which bone cells 
can be efficiently degraded (Gimona et al., 2003). The podosomes of lymphocytes bear 
pores through endothelial cells (Carman et al., 2007). Highly motile cancer cells have 
been shown to possess sites of rapid actin polymerization and matrix degradation. 
These sites are podosome-like actin-rich structures, and are called invadopodia 
(Weaver, 2006).  
 
When the leading edge of a migratory cell connects with the substratum, many integrin 
containing adhesion structures are formed inside the cell. These adhesion structures 
unite to form focal adhesions (FAs) which are the sites of actin cytoskeleton attachment 
within the cell (Geiger et al., 2009). FAs are one of the most well characterized adhesive 
structures that are made up of transmembrane integrin receptors and they are 
responsible for cell traction and reorganization of ECM (Albiges-Rizo et al., 2009). 
Invadopodia and podosomes both have a central actin-based machinery that is 
surrounded by multimeric protein complex of integrins and its associated proteins like 
talin, vinculin and paxillin (Desai et al., 2008; Mueller et al., 1992). In the case of FAs, 
the relationship between the actin-based machinery and associated proteins in not well 
understood. It is known that vinculin transiently associates with the Arp2/3 complex 
when cells attach to fibronectin (DeMali et al., 2002). Focal adhesion kinase (FAK) may 
influence actin stress fiber formation. FAK has been shown to interact with Arp2/3 
complex and WASP, and it is postulated that FAK and Arp2/3 may interact during early 
cell spreading (Serrels et al., 2007).  
 
Through the processes of cell migration and invasion, tumor cells enter the lymphatic or 
blood vasculature, and are taken to distant organs where they may form metastasis 
(Chambers et al., 2002). Cancer cells produce proteases that are required to physically 
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invade into the vasculature by the process of proteolytic degradation. The tumor stroma 
provides the principal source of proteases such as matrix metalloproteinases (MMPs), 
cysteine cathepsins and serine proteases (Joyce and Pollard, 2009). Activated 
fibroblasts secrete MMPs that enable tumor cells to invade local tissues and also detach 
from the primary tumor (Kalluri and Zeisberg, 2006). MMP3, produced by fibroblasts, 
has been shown to directly affect cancer cell motility and invasiveness (Lochter et al., 
1997). The mechanisms by which proteases lead to invasion and intravasation include 
cleaving cell-adhesion molecules like E-cadherin, that leads to disruption of cell-cell 
junctions (Masterson and O’Dea, 2007). Once the cellular junctions are disabled, cancer 
cells are able to migrate into the surrounding tissues and vasculature. Tumor associated 
macrophages (TAMs) play a critical role in tumor progression by driving cell invasive 
phenotypes at the leading edge of the tumor (Condeelis and Pollard, 2006). Aside from 
their roles in facilitating invasive phenotypes, TAMs secrete proteases such as cysteine 
cathepsins that work towards promoting tumor progression (Shree et al., 2011).  
 
In order to invade local tissues, tumor cells utilize the same basic strategies that are 
used by non-neoplastic cells during physiological processes like embryonic 
morphogenesis and wound healing. Additionally, tumor cells are able to use different 
modes of motility to infiltrate neighboring tissue matrices. They either move as single 
cells to bring about ‘individual cell migration’, or they disseminate in solid cell sheets or 
clusters, known as ‘collective migration’ (Friedl and Wolf, 2003).  
 
1.2.3.3 Survival of CTCs in circulation and extravasation 
 
From the millions of cancer cells shed into circulation, only about 0.01% survive to 
produce metastases (Fidler, 1970). Shear forces in the circulation that lead to 
mechanical destruction of these CTCs or immune surveillance by natural killer (NK) 
cells contribute to making the blood a difficult environment for the cancer cells to survive 
(Joyce and Pollard, 2009). Cancer cells can express the receptors for coagulation, 
namely VIIa and X, leading to platelet aggregation that acts as a shield for the cancer 
cells and protects them from shear forces and also NK cell-mediated lysis (Palumbo et 
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al., 2007). Intravital video microscopy has allowed the extravasation of CTCs into 
different organs like lung, liver and brain to be studied (Condeelis and Segall, 2003). It 
has been shown by real-time imaging that extravasation through endothelial capillaries 
involves active transmigration through holes in the vascular wall (Kienast et al., 2010). 
Studies on metastatic and non-metastatic cells show that CTCs that will not produce 
metastases may still retain the ability to extravasate (Schlüter et al., 2006; Kienast et al., 
2010).  
 
1.2.3.4 The metastatic tumor microenvironment 
 
It has been widely accepted that the interactions between the tumor cells and its 
microenvironment largely regulate formation of metastases. Way back in 1889, Stephen 
Paget, an English surgeon put forth a landmark concept of ‘seed and soil’ to explain the 
process of metastasis, when he wrote “When a plant goes to seed, its seeds are carried 
in all directions. But they can only live and grow if they fall on congenial soil.” He argued 
that cancer cells (seeds) could grow to form secondary tumors only in certain organs 
(soil) that were somehow predisposed (Paget, 1889). More recent studies point out the 
ability of the primary tumor to secrete certain factors that home the tumor cells to 
particular organs. MDA-MB-231 xenograft tumors on one side of the mouse, were 
shown to secrete osteopontin and hence mobilize bone marrow precursors to home to 
secondary sites where a less malignant cell line could grow (McAllister et al., 2008). In 
organ-specific dissemination, chemokines and their receptors have been implicated. 
Tumor cells express cognate receptors on their surface and through these, detect 
chemokines expressed in specific organs and respond with increase in chemotaxis and 
invasiveness (Müller et al., 2001). Breast cancer cells express CXCR4 and CCR7, and 
lung, liver and bone marrow exhibit peak levels of expression of their cognate ligands, 
SDF-1/CXCL12 and CCL12. These organs – lung, liver and bone marrow - represent 
important sites of breast cancer metastasis. Signaling through the chemokine receptors 
CXCR4 and CCR7 results in actin polymerization and pseudopodia formation and 
induces chemotactic and invasive responses in breast cancer cells (Müller et al., 2001).  
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In line with Paget’s hypothesis of metastasis, and in fact, furthering the idea is the 
concept of metastatic niche and the stromal progression model of metastasis (Psaila 
and Lyden, 2009; Sleeman et al., 2012). These concepts highlight the role of 
microenvironmental conditions local to the cancer cells, that potentially affect the growth 
and survival of these DTCs. Formation of a metastatic niche can be dictated remotely 
by factors produced by the primary tumor, before the DTCs arrive at secondary sites 
(called the pre-metastatic niche), and also by modification of the microenvironment 
endogenous to the organ where metastasis would develop (Sleeman, 2012). VEGFR1+ 
bone marrow-derived hematopoietic progenitor cells home to tumor-specific pre-
metastatic sites where they form cellular clusters before the arrival of DTCs (Kaplan et 
al., 2005). Tumors produce VEGF-A, TGF-ß and TNF-a, which leads to secretion of 
chemoattractants like S100A8 and S100A9 at the sites of future metastasis. These 
chemoattractants stimulate expression of SAA3 that induces recruitment of CD11b+ 
myeloid cells to these sites (Hiratsuka et al., 2006). Remodeling of ECM and 
vasculature, recruitment of BMDCs, hypoxia, the presence of non-neoplastic cells such 
as endothelial cells and fibroblasts, all constitute the functional elements of the 
metastatic niche (Sleeman, 2012; Sleeman and Cremers, 2007).  
 
Upon extravasation, not all the DTCs are capable of forming metastases. Some either 
die or remain dormant. In some cases, cancer cells have been reported to be dormant 
for years, and the seeding of these cells may have occurred several years before the 
diagnosis of the primary tumor (Aguirre-Ghiso, 2007). In other cases, dormant cells 
maintain a balance of proliferation and apoptosis, and in the absence of an appropriate 
blood supply, form micrometastasis that do not further develop into overt metastasis. 
This phenomenon has been termed ‘angiogenic dormancy’ (Holmgren et al., 1995).  
 
The metastatic niche plays a deciding role in whether the DTCs survive, become 
dormant or develop into metastases. The functional components of the niche, along with 
the cues from the primary tumor, have a crucial role in determining the fate of DTCs 
(Sleeman, 2012). An integrative model, the stromal progression model, has been 
proposed to explain the process of metastasis (Sleeman et al., 2012). According to this 
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model, tumor intrinsic properties, for example, genetic aberrations in the primary tumor, 
driven by an increased genomic instability and epigenetic changes, are not the only 
factors that decide whether the tumor will progress into fulminant metastases. Stromal 
progression, marked by modification of ECM, recruitment of BMDCs and non-
transformed cells like fibroblasts, induction of angiogenesis, occurs in parallel. As the 
tumor cells are exposed to new microenvironments at each step of the metastasis 
cascade, the tumor-stroma undergoes further changes, and this mutual and 
interdependent cross-regulation between the tumor and the stromal components drives 
tumor progression as a whole (Sleeman et al., 2012).  
 
 
 
Figure 6. Most common sites of breast cancer metastasis. 
Graphical representation of the most common sites of breast cancer metastasis. These include 
lung, liver and bone. (Weigelt et al., 2005).  
 
Upon dissemination, breast carcinoma cells form metastases in various organs (Figure 
6), with lung, bone and liver being the common sites for metastasis. About 10-15% of 
the breast cancer patients develop an aggressive disease and show metastases within 
3 years of initial diagnosis of the primary tumor. There are also cases where patients 
manifest metastases 10 years or more after the initial detection (Weigelt et al., 2005). 
© 2005 Nature Publishing Group 
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MULTIVARIATE ANALYSIS
A statistical test that examines 
more than two variables at the 
same time.
PROSPECTIVE STUDY
A study in which a selected 
group of patients is followed 
over time to determine 
differences in the rate at which 
disease develops in relation to 
the investigated factor. These 
factors might include drugs, 
procedures or diets.
PREDICTIVE MARKER
A characteristic of a patient that 
is associated with the response 
or lack of response to a 
particular therapy.
metastasis devel p ent. To m et the req irements 
of a prognostic marker, the potential marker should 
be tested retrospectively in large patient cohorts with 
a long follow-up period. MULTIVARIATE ANALYSIS needs 
to be done in conjunction with e tablished mark-
ers to assess its independent value. Subsequently, 
the findings should be validated by an independent 
group of researchers, and, ideally, a PROSPECTIVE STUDY 
should confirm the prognostic significance of the 
tested marker26,27.
A large number of putative molecular prognostic 
markers have been reported in the literature, but only 
a few of these have so far fulfilled the above described 
requirements TABLE 2. Preliminary data indicate that 
nearly all these markers are only of prognostic benefit 
in certain subgroups, or are not independent of the 
established markers25. Many other markers are still 
under clinical investigation.
So, what are the most promising recently devel-
oped prognostic markers, and what is their potential 
to accurately predict metastatic potential and patient 
outcome?
ERBB2. Among many biomarkers epidermal gorwth 
factor receptor 2 (ERBB2; also known as HER2/neu) 
has raised much attention as a possible prognostic 
marker. The human ERBB2 proto-oncogene encodes 
a transmembrane receptor with constitutive tyrosine-
kinase activity. ERBB2 is overexpressed due to gene 
amplification in 15–30% of human breast cancers28,29. 
The prognostic value of ERBB2 was first claimed in 
1987 REF. 28, and from then on it has been extensively 
studied. Ross and colleagues recently reviewed the 
published literature concerning ERBB2, including 81 
studies and 27,161 patients30. Most studies reported 
that ERBB2 amplification or overexpression is asso-
ciated with poor outcome in patients with axillary-
lymph-node metastases, but it is not associated with 
poor outcome in patients with tumour-negative lymph 
nodes30. However, the ERBB2 status of breast tumours 
has gained clinical relevance due to the introduction 
of trastuzumab, a therapeutic monoclonal antibody 
that is directed against the receptor, and which helps 
prolong survival in patients with metastatic breast 
cancer29. Moreover, increasing evidence also indicated 
that ERBB2 might be a PREDICTIVE MARKER for response 
to adjuvant chemotherapy and endocrine therapy 
(reviewed in REFS 31,32). This might explain why the 
testing of newly diagnosed breast cancer specimens for 
ERBB2 status has achieved ‘standard of practice’ status 
for the management of breast cancer. This is despite 
the prognostic value of ERBB2 for disease-free and 
overall survival in patients with lymph-node-positive 
breast cancer being specified as weak-to-moderate 
by the World Health Organization Classification 
of Tumours12. Clearly, additional well-controlled 
and well-designed studies with sufficient follow-up 
time must be conducted to adequately validate the 
prognostic significance of ERBB2.
Detection of disseminated tumour cells. To establish a 
metastasis, tumour cells have to invade their surround-
ing host tissue, enter the circulatory blood stream, arrest 
in capillary beds of distant organs, invade the host tissue 
and proliferate. As small tumours of less than 2 mm in 
diameter already receive a vascular blood supply33, it is 
likely that cancer cells have spread throughout the body 
years before they are first detected. The development 
of an assay to detect these cells before the manifesta-
tion of distant metastases might therefore be useful for 
patient prognosis. The search for circulating tumour 
cells started in the late 1980s, and today both immu-
nohistochemical staining and PCR-based approaches 
are available to detect disseminated tumour cells. These 
methods are based on the presence of breast epithelial 
markers, in peripheral blood, bone marrow and lymph 
nodes (reviewed in REF. 34).
Owing to technical issues regarding the rarity of 
the disseminated cells and the background expres-
sion levels of these markers, only a few studies 
have been published that examine the relationship 
between the presence of circulating tumour cells in 
peripheral blood and patient outcome. Two clinical 
studies showed that the disseminated-tumour-cell 
load in peripheral blood is associated with shortened 
disease-free intervals and reduced overall survival in 
patients with early breast cancer35,36. Stathopoulou 
et al. tested the peripheral blood of 148 patients 
for cytokeratin-19 mRNA35, whereas Zach and 
colleagues tested 310 patients for mammaglobin 
mRNA36, both using a nested reverse transcriptase 
(RT)-PCR approach. Although both studies selected 
patients with operable breast cancer, the incidence 
of patients with positive tests varied. Stathopoulou 
et al. found 44 patients (30%) to be positive for cytok-
eratin-19 mRNA, of whom 19 developed a metastasis, 
whereas Zach et al. detected mammaglobin mRNA 
in only 5 patients (2%), who all developed distant 
metastases. Remarkably, the detection of putative 
circulating tumour cells predicts early recurrence 
at distant sites in patients with breast cancer; in the 
Figure 1 | Most common metastasis sites of breast cancer at autopsy. Primary breast 
cancer cells metastasize through the blood vessels to various distant organs, preferentially, to 
the lung, liver and bones. Patients frequently develop metastases at multiple sites. Data adapted 
from REF. 13.
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Breast cancer patients are therefore at a lifetime risk of developing metastasis. In-depth 
studies on genes that promote breast tumor progression is therefore required to fully 
understand the heterogeneous nature of the disease.  
 
1.3 Asap1 and cancer: rationale of the study 
 
Subsequent to its identification in a metastasis-associated gene expression profile, our 
lab showed that as compared to the surrounding non-neoplastic tissue, ASAP1 
expression was upregulated in a wide variety of human tumor types including 
carcinomas of the stomach, gall bladder, colon, breast, ovary, and esophageal and 
head and neck squamous cell carcinoma (HNSCC) (Müller et al., 2010). Its expression 
correlated with poor metastasis-free survival and poor overall survival in human 
colorectal cancer patients, and it was found to promote cell adhesion, motility and 
invasion and in vivo metastasis formation in a syngeneic rat pancreatic cancer model 
(Müller et al., 2010). Other groups have also reported association of high levels of 
ASAP1 with tumor progression and metastasis. For example, increased levels of 
ASAP1 corresponds to poor prognosis and survival after surgery of HNSCC patients 
(Sato et al., 2014), poor prognosis in epithelial ovarian cancer (Hou et al., 2014) and 
metastasis of prostate cancer (Lin et al., 2008). An oncogenic role for ASAP1 in the 
metastasis of laryngeal tumors has also been described (Li et al., 2014).  
 
1.3.1 Asap1 and breast cancer: what is known so far 
 
Overexpression of ASAP1 has been correlated with malignancy of primary ductal 
carcinoma of the human breast (Onodera et al., 2005). Most of the current knowledge 
about how ASAP1 may be involved in the metastasis of breast carcinoma comes from 
cell line-based models or retrospective studies on patient data. There is evidence to 
suggest that the EGFR-GEP100-Arf6-ASAP1 signaling pathway is upregulated in 
malignant breast cancer and used for invasion and metastasis (Onodera et al., 2005). 
Specifically, co-expression of EGFR and GEP100 (a GEF for Arf6) correlates with 
malignant breast cancer (Morishige et al., 2008). Ligand activated EGFR directly binds 
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to GEP100 to activate Arf6 (Someya et al., 2001). Activation of GEP100 by Arf6 
perturbs E-cadherin-based cell-cell adhesion of breast cancer cells, and may induce 
their motile phenotypes (Morishige et al., 2008). Importantly, activated Arf6 recruits 
ASAP1 to this complex by direct binding (Hashimoto et al., 2005).   
  
Cortactin is a multi-domain protein that is found in the peripheral membrane ruffles and 
invadopodia. ASAP1 and cortactin associate with invadopodia in invasive breast cancer 
cell lines (Onodera et al., 2005). It has been shown that ASAP1 and cortactin together 
form an invasive machinery that links the highly tubulated membranes found in 
invadopodia and podosomes to polymerized and branched actin (Randazzo et al., 
2007). Taken together, these observations suggest that ASAP1 is likely implicated in 
molecular regulation of the invasive phenotype. 
 
1.3.2 Tools for studying the role of Asap1 in breast cancer 
 
Given the correlation of ASAP1 with metastasis of cancer types including breast cancer, 
it is pertinent that the molecular biology underlying this association and the function of 
ASAP1 should be studied in detail. For this purpose, Asap1 knockout mice have been 
generated in our lab (data unpublished). My thesis set out to breed these mice with 
autochthonous mouse models of breast cancer as a pre-clinical model to understand 
the role of ASAP1 in breast cancer metastasis. The next sections therefore describe 
these animal models in more detail. 
 
1.3.2.1 Engineering of Asap1 knockout mice 
 
One way to knock out genes in the mouse germline in a high throughput manner is to 
create a gene trap vector that carries a promoterless lacZ gene, a splice acceptor 
upstream to it and an antibiotic resistance marker. Mouse embryonic stem (ES) cells 
are then transfected with the gene trap vector. Random intronic integration of the gene 
trap vector into genes in the cells results in disruption of endogenous expression (von 
Melchner and Ruley, 1989). As depicted (Figure 7), upon transcriptional activation of the 
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gene, a spliced transcript arising from the upstream exon of gene of interest and lacZ 
gene, is generated. Thus not only is expression of the gene disrupted, expression of the 
lacZ gene serves as an indicator of when the disrupted gene would normally be 
expressed. Successfully transfected ES cells are screened to determine which gene 
has been targeted, and can then be used to create knockout mice through standard 
blastocyst injection methods.  
 
This gene trap vector approach was used to create Asap1 knockout mice. Insertion of 
the gene trap vector into the second intron of the mouse gene locus of Asap1 was 
confirmed by whole genome sequencing. As the promoter of Asap1 drives the 
expression of the lacZ gene, the normal expression pattern of ASAP1 can easily be 
detected by way of β-gal staining. The Asap1 mice carrying the gene trap are 
designated as Asap1GT/GT since in these mice, both the alleles for Asap1 have been 
replaced by the gene trap. They represent an Asap1 knockout mice population. The 
Asap1 heterozygous mice and the wild-type mice are denoted as Asap1+/GT and 
Asap1+/+ respectively, as in them either one or none of the Asap1 alleles has been 
replaced by the gene trap. 
 
Complete abrogation of the endogenous expression of Asap1, as confirmed by RT-PCR 
analysis on a mouse embryo of stage E11.5 carrying the gene trap, demonstrated 
successful integration of the gene trap into mouse Asap1 locus (Figure 8). Sometimes 
utilizing the gene trap strategy could lead to a scenario where hypomorphic alleles are 
generated due to alternative splicing, mainly because the insertion event has taken 
place in an intron. This could result in low expressions of the endogenous gene 
transcripts (McClive et al., 1998). To rule out any possibility of expression of Asap1 
arising from alternative splicing, the exons downstream of the gene trap insertion site 
(exons 11-13, exons 21-24, exons 29-30) were analyzed for Asap1 expression. The 
expression was also checked at the protein level and it was found that Asap1GT/GT 
embryos were incapable of expressing endogenous ASAP1.  
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Figure 7. Strategy for trapping Asap1. 
(A) Schematic representation of gene trap vector insertion into Asap1 gene locus. Upon a 
successful insertional event where the gene trap integrated into the intron of Asap1, a fusion 
transcript was generated during the process of transcription. Asap1 promoter drives the 
expression of promoterless lacZ gene. The Asap1 is thus trapped and reported. (B) Gene trap 
vector was introduced into intron 2 of mouse Asap1 gene locus at chromosome 15 thereby 
replacing exon 3 and a part of intron 2, leading to disruption of endogenous expression of 
Asap1. The site of gene trap insertion was determined by genomic sequencing.  
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Figure 8. Validation of generation of Asap1 knockout mice. 
(A) RT-PCR analysis of E11.5 embryos confirm deletion of Asap1. (B) Asap1 mRNA expression 
from exons downstream of site of gene trap introduction was checked to validate gene trap 
insertion event. None of the exons expressed Asap1, therefore any possibility of a partial 
expression of Asap1 arising likely from any alternative splicing is ruled out. Asap1 expression is 
completely abrogated. (C) Western blot showing no expression of Asap1 at protein level 
corroborates Asap1 deletion in our mouse model. Experiment and analysis performed by Dr. 
Caroline Schreiber and Dr. Natascha Cremers, CBTM, Mannheim.  
 
 
At the start of my PhD thesis work, Asap1GT/GT mice had been generated, but their 
phenotype had been little investigated. Therefore, one of my tasks was to investigate 
the effect of loss of ASAP1 on normal physiology.  
 
1.3.2.2 Murine models of breast cancer progression 
 
One aim of my PhD thesis was to understand how Asap1 regulates breast tumor 
progression. To this end, specific mouse models of breast cancer were bred with 
knockout mice and tumor growth in these mice was studied. The genetically engineered 
mouse models (GEMM) used recapitulate events observed in human breast cancer by 
forming spontaneous tumors when an oncogene is expressed in the mammary 
epithelium via a tissue-specific promoter. The most frequently utilized promoter is the 
mouse mammary tumor virus (MMTV) promoter that has been used to drive the 
expression of many oncogenes like Ras, Her2 (Neu), Cox2, polyoma middle T antigen 
(PyMT) and Wnt1 in the mammary epithelium, resulting in the formation of breast 
cancers (Fantozzi and Christofori, 2006).  
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MMTV-Neu  
Primary human breast cancers can carry amplification and overexpression of the proto-
oncogene HER2, which inversely correlates with the survival of the patients (King et al., 
1985). The rodent homologue of HER2 is neu. HER2/neu is a 185-kDa transmembrane 
protein belonging to the EGF receptor family. To study the tumorigenic potential of this 
oncogene in the mammary epithelium of transgenic mice, mice lines carrying either the 
activated or the unactivated rat neu under the transcriptional control of the MMTV 
promoter have been generated (Bargmann and Weinberg, 1988; Guy et al., 1992a). In 
my thesis work I have utilized the unactivated neu oncogene, driven by the MMTV 
promoter. In MMTV-Neu (unactivated) transgenic mice, focal mammary tumors appear 
at about 4 months of age, independent of pregnancy status. Histologically, these tumors 
are identical to those formed by activated neu. The oncogene neu has been shown to 
have intrinsic tyrosine kinase activity, and this has been associated with its tumorigenic 
potential. Consistently, neu-induced tumors have been shown to exhibit increased 
tyrosine kinase activity compared to the adjacent mammary epithelia. Mammary gland-
specific expression of neu has been documented to induce metastases to the lung, in 
mice that have borne tumors for several months (Guy et al., 1992a).  
 
MMTV-Wnt1 
The Wnt1 gene encodes a member of a family of poorly soluble, glycosylated, cysteine-
rich, secretory proteins. The Wnt family of proteins associate with the ECM and 
determine cell fate and patterning via their interactions through cell surface receptors. 
Overexpression of several of the Wnt family members has been associated with the 
transformation of cultured cells. Wnt1 overexpression has been shown to 
morphologically transform mammary epithelial cells (Li et al., 2000). A Wnt1 transgene 
driven by the MMTV promoter in mice induces increased alveolar and ductal 
hyperplasia, independent of the pregnancy status (Tsukamoto et al., 1988). Metastasis 
was not reported at the time of detection of tumors, but the majority of the Wnt1 
transgenic mice showed lung and/or lymph node metastasis after the primary tumor was 
removed (Li et al., 2000).  
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MMTV-PyMT 
Polyoma virus middle T antigen (PyMT) is associated with a strong tyrosine kinase 
activity, like the neu oncogene, and has been implicated in murine mammary 
carcinogenesis (Guy et al., 1992b). The tumorigenic capacity of PyMT is mainly 
attributable to its association and subsequent activation of many c-src family members 
and its interaction with a subunit of phosphatidylinositol 3’-kinase (PI3K). MMTV-PyMT 
transgenic mice develop multifocal mammary tumors and multiple foci of metastatic 
mammary adenocarcinomas in the lung parenchyma. The transgenic mice display a 
short latency period between the expression of the transgene and transformation of the 
mammary epithelium, and this suggests that the expression of middle T oncogene is 
sufficient for the induction of mammary carcinogenesis in these mice, without the 
requirement of any additional genetic events (Guy et al., 1992b). The frequent 
occurrence of pulmonary metastasis in MMTV-PyMT transgenic mice allows for a 
systematic monitoring of mammary tumor progression in this model.  
 
1.4 Objectives of the study 
 
In my thesis work my major objective was to understand the function of Asap1 in normal 
physiology as well as its role in breast tumor metastasis. I had the following specific 
aims: 
 
1. Characterize Asap1 knockout mice and determine the knockout phenotype. 
 
2. Establish whether loss of Asap1 affects tumor formation and metastasis in 
transgenic mouse models of breast cancer. 
 
3. Understand the role of Asap1 in tumor metastasis at the cellular level by studying 
murine mammary tumor cells and murine fibroblasts.  
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2. Materials and Methods 
 
2.1 Materials 
Material Company 
Acetic acid Roth, Karlsruhe 
Acetone Merck, Darmstadt 
Acrylamide/N, N’-Methylene -
bisacrylamide (37,5:1) Roth, Karlsruhe 
Agarose Sigma, Taufkirchen 
Ammonium peroxodisulfate (APS) Roth, Karlsruhe 
BCA protein assay kit Thermo Fisher Scientific, Schwerte 
Bovine serum albumin Roth, Karlsruhe 
Bromophenol blue Roth, Karlsruhe 
Butanol Roth, Karlsruhe 
Cell culture plastic ware BD Biosciences, Heidelberg 
Chloroform Sigma, Taufkirchen 
Dako pen Dako, Hamburg 
Deoxynucleoside triphosphates – 
dNTPs Peqlab, Erlangen 
Diamidinophenylindole (DAPI) Sigma, Taufkirchen 
Diethylpyrocarbonate (DEPC) Sigma, Taufkirchen 
Dimethylsulfonyloxide (DMSO) Sigma, Taufkirchen 
Disodium hydrogen phosphate Roth, Karlsruhe 
Dithiothritol (DTT) Fluka, Neu-Ulm 
Dream Taq DNA polymerase and 
buffer Thermo Fisher Scientific, Schwerte 
Dulbecco modified eagle medium 
(DMEM) Life Technologies, Darmstadt 
ECL, western blotting substrate Thermo Fisher Scientific, Schwerte 
Eosin Merck, Darmstadt 
Epidermal growth factor (EGF) Sigma, Taufkirchen 
Ethanol Roth, Karlsruhe 
Ethidium bromide Roth, Karlsruhe 
Ethylenediaminetatraacetic acid Thermo Fisher Scientific, Schwerte 
Eukitt Kindler GmBH, Freiburg 
Fetal calf serum Life Technologies, Darmstadt 
Fibronectin Millipore 
Fluoromont-G Southern Biotech 
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Material Company 
Gelatin Roth, Karlsruhe 
GeneRuler DNA Ladder Thermo Fisher Scientific, Schwerte  
Glutamine  Invitrogen, Karlsruhe 
Glycerin Roth, Karlsruhe 
Glycerol Roth, Karlsruhe 
Glycine Roth, Karlsruhe 
H2O2 Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
Mayer’s Haematoxylin solution Merck, Darmstadt 
Medical X-ray film Typon Roentgen-Film, Frankenthal 
Methanol Roth, Karlsruhe  
Nonidet P 40 Sigma, Taufkirchen 
Oligonucleotides Metabion 
Opti-MEM Life Technologies, Darmstadt 
PageRuler Plus Protein ladder Thermo Fisher Scientific, Schwerte 
Paraformaldehyde Roth, Karlsruhe 
Penicillin/Streptomycin Life Technologies, Darmstadt  
Phalloidin Promokine 
Phenol Roth, Karlsruhe 
Phosphate buffered saline  Life Technologies, Darmstadt 
Potassium chloride Roth, Karlsruhe 
Potassium dihydrogen phosphate Roth, Karlsruhe 
Powdered milk Roth, Karlsruhe 
Power SYBR Green Master Mix Applied Biosystems, Darmstadt  
Protease inhibitor complex Roche Diagnostics, Mannheim 
Proteinase K Dako, Hamburg 
Roti-Histol Roth, Karlsruhe 
Sodium chloride Roth, Karlsruhe 
Sodium deoxycholate Sigma, Taufkirchen 
Sodium dodecyl sulfate Roth, Karlsruhe 
Sodium hydroxide Roth, Karlsruhe 
Tetramethylethylendiamine (TEMED) Roth, Karlsruhe 
Tissue Tek O.C.T Sakura 
Tris HCL, Tris base Roth, Karlsruhe 
Triton X 100 Sigma, Taufkirchen 
Trizol Invitrogen, Karlsruhe 
Trypsin Invitrogen, Karlsruhe 
Tween 20 Roth, Karlsruhe 
β mercaptoethanol Sigma, Taufkirchen 
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2.2 Equipment 
Equipment Company 
Axio Imager.D1 Carl Zeiss, Jena 
Cawomat 2000R CAWO, Schrobenhausen 
Centrifuges Thermo Fisher Scientific, Schwerte 
Diaphragm pump Vacuubrand, Wertheim 
DMI6000b microscope Leica Microsystems, Wetzlar 
Electrophoresis apparatus Peqlab, Erlangen; Biorad, Muenchen 
ELISA reader Multiscan Ascent Thermo Fisher Scientific, Schwerte 
Incubators 
Binder, Tuttlingen; Thermo Fisher 
Scientific, Schwerte  
NanoDrop ND-8000 spectrophotometer  NanoDrop Tech, Wilmington, USA 
Paraffin embedding station EG1160 Leica, Wetzlar  
PCR cycler Analytic Jena, Jena 
SLEE CUT 4060 SLEE medical, Mainz 
Sterile hood Hera Safe Thermo Fisher Scientific, Schwerte 
Thermomixer 5436 Eppendorf, Hamburg 
Tissue lyzer II Qiagen, Duesseldorf 
UV transilluminator INTAS, Goettingen 
Vortex VWR International, UK 
Water bath Memmert, Buechenbach   
 
2.3 Antibodies 
Antigen Host Species Reactivity 
Application 
Comment 
Concentration 
Used Company 
ASAP1 Mouse Mouse IF 5 µg/ml Lab produced 
SLK Rabbit Mouse WB 2 µg/ml Abcam 
  
  
IF/IHC 20 µg/ml 
 β-actin Mouse Mouse WB 1:10,000* Sigma 
Vinculin Mouse Mouse IF 5 µg/ml Sigma 
Tubulin Rabbit Mouse IF 5 µg/ml Abcam 
Secondary 
AlexaFluor 
(546/488) 
Goat Rat  IF 4 µg/ml Invitrogen 
Goat Rabbit IF 4 µg/ml Invitrogen 
Goat Mouse IF 4 µg/ml Invitrogen 
CK14 Rabbit Mouse IHC 10 µg/ml Covance 
CK18 Mouse Mouse IHC 2 µg/ml 
Progen 
Biotechnik 
α-SMA Mouse Mouse IHC 1:100* Sigma 
*Antibody concentration not provided. 
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2.4 Oligonucleotides 
All oligonucleotides are specific for genes in mus musculus, purchased from Oligos 
Metabion and ordered with standard purification procedure (desalted).  
 
Name Sequence (5’ → 3’) 
ASAPgeneTrap3´for TCGATGTAACCCACTCGTGC 
ASAPgeneTrap3´rev CTACTTACTCCTACATCTGAGATCC 
ASAPgenomic5 for GCATCGCCTGTCATCCTACA 
RibPO for GGACCCGAGAAGACCTCCTT 
RibPO rev GCACATCACTCAGAATTTCAATGG 
 
2.5 Cell lines 
All cells were cultured in DMEM containing 10% FCS, 1% L-glutamine and 1% 
penicillin/streptomycin and were maintained at 37°C in a humidified incubator in 5% 
CO2 supply. 
 
Cell Type Cell Line Source 
Murine Embryonic 
Fibroblasts (MEFs) 
Asap1+/+ 
fibroblasts E13.5 Asap1
+/+ embryo 
Asap1GT/GT 
fibroblasts E13.5 Asap1
GT/GT embryo 
Primary tumor derived 
cell lines 
PyMT Asap1+/+ 
tumor cells MMTV PyMT Asap1
+/+ tumor  
PyMT Asap1GT/GT 
tumor cells MMTV PyMT Asap1
GT/GT tumor  
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2.6 Tissue culture methods 
 
2.6.1 Cell culture maintenance 
Cells were maintained at 37°C in a humidified incubator with 5% CO2 supply. They were 
grown until they were 80-90% confluent, after which they were detached by 
trypsinization and re-seeded at lower density. Trypsin and the culture medium were pre-
warmed at 37°C before they were applied onto the cells. Briefly, culture medium was 
aspirated and cells were washed with PBS. Cells were detached using 0.25% trypsin, 
and were incubated for a short time at 37°C to speed up the detachment process. Fresh 
medium was added to the detached cells and cells were spun down into a pellet, to be 
re-suspended and plated at desired densities. All cell lines were routinely screened for 
mycoplasma infection using the VectorGem Myco Detection kit from Vector. For long-
term storage of cells, they were stored in freezing medium (90% FCS, 10% DMSO) at -
80°C or in liquid nitrogen. The freezing process began when the cells reached about 
80% confluence. For this purpose they were harvested and centrifuged at 1000 rpm for 
3 minutes. Medium was aspirated and the cell pellet was re-suspended in freezing vials 
in 1 ml of freezing medium. They were transferred to -80°C for a few days and then later 
to liquid nitrogen. When required, cells were thawed through fast warming at 37°C in a 
water bath, following dilution in 5 ml of fresh medium. Cells were spun down to a pellet 
and re-suspended in fresh medium, to remove residual DMSO.  
 
2.6.2 Isolation of Mouse Embryonic Fibroblasts (MEFs) 
Pregnant FVB, Asap1+/GT mice were utilized to isolate embryonic fibroblasts. The 
experimental animals were maintained under specific pathogen free (SPF) conditions at 
the animal facility of Institute for Toxicology and Genetics, at Karlsruhe Institute of 
Technology. The pregnant mice, usually at F7 generation, were sacrificed by cervical 
dislocation on embryonic day 13.5. In a sterile hood, the abdomen was swabbed with 
70% ethanol then cut open to expose the uterine horns, which were immediately 
transferred to a clean Petri dish containing PBS and placed on ice during the entire 
procedure. Embryos were carefully dissected in fresh Petri dishes to avoid any 
contamination with maternal tissue. Yolk sac was removed and later used for 
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genotyping. Head, heart, liver and spleen were removed from the embryo and the rest 
of the tissues from the embryo was cut into small pieces. These were washed in cold 
PBS once and then allowed to settle on ice. After aspirating PBS, the cut tissues from 
each embryo were transferred to Falcon tubes containing cold 0.25% trypsin. Tissue-
digestion was allowed to occur at 37°C for 20 minutes, after which, 5 ml of warm media 
was added to the tubes and lysed tissue was gently homogenized by pipetting up and 
down to obtain single-cell suspension. Before plating onto a 10 cm dish, 5 ml fresh 
medium was added to this suspension. On the next day, the medium was aspirated to 
remove cell debris and fresh medium was added. Following genotyping results, MEFs 
from Asap1+/+ and Asap1GT/GT were identified and stored in freezing medium at -80°C or 
liquid nitrogen for long-term storage.  
 
2.6.3 Isolation of MMTV-PyMT Asap1+/+ and – Asap1GT/GT tumor derived cells 
Tumors from MMTV-PyMT Asap1+/+ and – Asap1GT/GT were isolated under sterile 
conditions. Briefly, tumor-bearing mice were sacrificed by cervical dislocation and their 
abdominal skin was cut open to expose the breast tumor. Mammary tumors were then 
carefully excised from the animals and placed on clean, sterile Petri dish. Using a sterile 
scalpel, the tumor was cut into fine pieces. Pre-warmed fresh medium was added to the 
finely cut tumor pieces and they were incubated in culture dishes overnight at 37°C. 
Tumor pieces that resisted being cut into smaller pieces were removed from the cell 
culture dish the following day using sterile forceps, and the medium was replenished. 
Cells were then allowed to grow until they achieved about 80% confluency. This usually 
took about 8-10 days. Medium was changed twice a week. Once cells were confluent, 
they were stored in freezing medium.  
 
2.6.4 Cell motility assay 
For each experiment, 5 x 105 cells/well from three Asap1+/+ and Asap1GT/GT (MEFs or 
tumor-derived) cell lines were seeded in 12 well plates. On the following day, a ‘wound’ 
was created in the monolayer of confluent cells by using a sterile 20 μl pipette tip. The 
scraped-out cells from creating the wound were washed away by changing the medium 
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and images were taken at desired time points. The distance between the cells fronts 
was analyzed with ImageJ software. Percentage wound healing was calculated. 
 
2.6.5 Cell spreading assay 
Cells at a density of 1 x 105 cells/well were seeded in slide chambers coated with 10 
µg/ml fibronectin for 30 minutes at room temperature. After incubation at 37°C for the 
desired time points, cells were fixed with 4% PFA for 10 minutes at room temperature. 
The chamber compartment was taken off the slides and slides were sealed with 
coverslips. Spread and non-spread cells were counted in five representative high power 
fields. Spread cells were defined as large, elongated cells, adhering to the substrate 
(fibronectin-coated slide) and non-spread cells were defined as small cells with no (or 
very little) membrane protrusions.  
 
2.6.6 EGF stimulation of MEF cells  
Coverslips were coated with 0.25% gelatin in PBS. Excess gelatin was aspirated and 
the coverslips were air-dried and placed in 6 cm cell culture dishes. Cells were serum-
starved for 6 hours, then harvested and seeded at 2 x 105 cells per 6 cm dish onto the 
coverslips. Cells were treated with 10 ng/ml EGF for the specified time points after 
which they were fixed in 4% PFA for 10 minutes at room temperature. They were then 
washed twice with PBS and either stored at 4°C or used immediately for 
immunofluorescence staining.  
 
2.6.7 Immunofluorescence staining 
Cells grown on coverslips were PFA fixed, then washed twice with PBS and treated with 
0.1% Triton X 100 in PBS for 2 minutes at room temperature to allow permeabilization. 
After three PBS washes, cells were blocked with goat serum for 1 hour at room 
temperature. Cells were then incubated with the desired primary antibodies diluted in 
0.1% goat serum/10% FCS/PBS for 1 hour at room temperature. Cells were washed 
again three times with PBS to get rid of excess antibodies and then incubated with 
appropriate secondary Alexa Fluor secondary antibodies diluted in 0.1% goat 
serum/10% FCS/PBS for 30 minutes in the dark, at room temperature. Wherever 
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phalloidin staining was required, it was added together with the secondary antibodies at 
specified concentrations. After secondary antibody incubation, cells were washed with 
PBS, three times, to remove excess antibody and then incubated with 0.5 µg/ml DAPI 
for 2 minutes in the dark at room temperature. After a final PBS wash, the coverslips 
were carefully turned onto microscopic slides with the cell-coated side facing down, and 
mounted with Fluoromont-G. The samples were kept at -20°C in the dark for at least an 
overnight before taking images. 
 
2.7 Biochemical methods 
 
2.7.1 Cell lysis 
To analyze protein expression, lysates from cells were prepared. After the medium was 
aspirated, cells were washed with ice-cold PBS and harvested using an appropriate 
volume of lysis buffer. After about 15 minutes of incubation of cells on ice, they were 
sonicated for 10 to 20 seconds at 50 or 60 Hz for mechanical disruption and to break 
the DNA. Cells were centrifuged at 13000 rpm for 5 minutes and protein concentration 
was determined using a commercially available bicinchoninic acid (BCA) assay kit, 
using a calibrated curve generated from known concentrations of bovine serum 
albumin. A 1:5 dilution of the lysate was used for the colorimetric assay. The color 
development in each sample was proportional to the amount of protein, and was 
measured at 595 nm with an ELISA reader. Protein concentration was calculated using 
Ascent software. Lysates containing 50-100 μg proteins were diluted with 4x sample 
buffer and incubated for 5 minutes at 95°C.  
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Reagent Concentration 
Lysis buffer 
Tris pH 7.5 50 mM 
Sodium Chloride 150 mM 
EDTA 5 mM 
Triton X 100 1% 
PMSF 1 mM 
Protease inhibitor cocktail 1x dilution 
Sample buffer 
SDS 8% 
Tris-HCl pH 6.8 100 mM 
Glycerin 40% 
Bromophenol blue 0.02% 
DTT 400 mM 
 
2.7.2 SDS-PAGE 
Protein samples were loaded onto SDS gels containing a stacking and a resolving part 
for separation of proteins based on size. The sample containing gel was run in running 
buffer, at 60-100 V until the dye front from the sample buffer reached the lower end of 
the gel.  
 
Reagent Concentration 
Stacking gel 
Acrylamide/bisacrylamide 3% 
Tris-HCl pH 6.8 125 mM 
SDS 0.10% 
APS 0.10% 
TEMED 0.10% 
Resolving gel 
Acrylamide/bisacrylamide 8-12% 
Tris-HCl pH 8.8 375 mM 
SDS 0.10% 
APS 0.10% 
TEMED 0.10% 
Running buffer 
Tris 25 mM 
Glycine 192 mM 
SDS 0.10% 
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2.7.3 Western blot 
Upon completion of SDS-PAGE, gels were incubated in transfer buffer for 10 minutes. 
The PVDF membrane was activated by soaking it in 100% methanol for 15 seconds and 
rehydrated in water for 2 minutes, after which it was equilibrated in transfer buffer for 5 
minutes. The blotting assembly was prepared using Whatman filter paper and sponges 
in the order, from cathode to anode: sponge pads, filter paper, gel, membrane, filter 
paper and sponge pads. Avoiding any air bubbles within this assembly, gels were 
electro-blotted on the membrane in transfer chambers filled with cold transfer buffer, 
overnight at 30 V at 4°C, and constant stirring. After transfer, the PVDF membrane was 
given a gentle wash with washing buffer and incubated with blocking buffer for an hour, 
at room temperature, followed by another hour of incubation (at room temperature) with 
the desired primary antibody diluted in blocking buffer. Excess antibody was washed 
away and the membrane was incubated with secondary horseradish peroxidase (HRP)-
conjugated antibodies at appropriate dilutions (made in blocking buffer). Incubations in 
blocking buffer and antibodies were carried out with gentle shaking. Protein bands on 
the membrane were visualized with the help of ECL (enhanced chemiluminiscence) 
pipetted onto the membrane. After a minute, the membrane was exposed to X-ray films 
for a few minutes, depending on signal strength.  
 
Reagent Concentration 
Transfer buffer 
Tris 20 mM 
Glycine 192 mM 
SDS 0.01% 
MeOH 20% 
Blocking buffer 
Tris-HCl pH 7.4 50 mM 
Sodium chloride 150 mM 
Tween-20 0.03% 
Powdered milk 4% 
Wash buffer 
Tris-HCl pH 7.4 50 mM 
Sodium chloride 150 mM 
Tween-20 0.03% 
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2.7.4 Preparation of Formalin-Fixed Paraffin Embedded (FFPE) tissues 
Fresh tissue (tumor and/or lung) isolated from the experimental animals was fixed in 
formalin overnight at room temperature and subjected to an automated dehydration 
procedure using a Hypercenter XP (Thermo Fisher Scientific) tissue processor with the 
following program: 
 
1. Formalin, 1.5 h, repeated twice 
2. 70% ethanol, 1.5 h 
3. 80% ethanol, 1.5 h 
4. 96% ethanol, 1.5 h 
5. 100% ethanol, 1.5 h 
6. Xylol, 1.5 h, repeated twice 
7. Paraffin, 1.5 h 
 
Samples were embedded in paraffin and stored at 4°C overnight before they were cut 
into 5 μM sections. These sections were allowed to dry overnight at 37°C and then 
immersed in Roti-histol (twice, 5 minutes each), followed by immersion in descending 
ethanol concentrations (100%, 96%, 80%, 70%; 2 minutes in each). The samples were 
then ready to be used either for immunohistochemistry or haematoxylin and eosin 
(H&E) staining.  
 
2.7.5 Immunohistochemical staining of FFPE-tissue 
Sections were incubated in citrate buffer (pH 6.0) at 60°C for 30 minutes to facilitate 
antigen retrieval. They were then cooled down and immersed in PBS for 5 minutes. 
Endogenous peroxidase activity was quenched by immersing samples in 3% H2O2 for 5 
minutes. Slides were then washed in PBS (twice, 5 minutes each) and blocked by 
incubation with 10% goat serum for 30 minutes. The desired primary antibody was 
diluted as required in blocking solution, and samples were incubated at 4°C overnight. 
The next day, slides were washed in PBS (3 times, 5 minutes each) and incubated with 
secondary antibody diluted in blocking buffer at 1:200 ratio at specified concentrations. 
Samples were incubated for 30 minutes at room temperature, after which they were 
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washed with PBS (3 times, 5 minutes each) and incubated with ABC reagent for 30 
minutes (prepared and incubated in the dark for 30 minutes at room temperature). This 
was followed by another PBS wash (3 times, 5 minutes each). Subsequently, the 
NovaRed peroxidase substrate was applied to the samples for 2 to 4 minutes or until 
visible coloration appeared on the sample. The samples were then washed in water for 
5 minutes. Slides were subsequently immersed in ascending concentrations of ethanol 
(70%, 80%, 96%, 100%; 2 minutes in each) and Roti-histol (3 times, 5 minutes each). 
The slides were covered in Eukitt mounting medium and mounted with coverslips.  
 
2.7.6 Haematoxylin and Eosin (H&E) staining of FFPE-tissue 
FFPE sections, after being treated with Roti-histol and decreasing concentrations of 
ethanol were immersed in haematoxylin for 10 minutes and the then placed under 
running tap water to wash off excess stain. Slides were then immersed in eosin for 5 
minutes and quickly passed through increasing concentrations of ethanol (70%, 80%, 
96%, 100%; 2 minutes each) and then in Roti-histol (3 times, 5 minutes each). Slides 
were then covered in Eukitt mounting medium and mounted with coverslips.  
 
2.8 Animal experiments 
All procedures involving mice were carried out in accordance with the local regulatory 
board (Regierungspraesidium, Karlsruhe). The FVB strain of mice was used in this 
study and mice were housed under specific pathogen free (SPE) conditions at the 
animal facility of Institute for Toxicology and Genetics, at Karlsruhe Institute of 
Technology. Light conditions (12 hours light, 12 hours dark) and temperature (21°C) 
were controlled, and mice were fed commercial mouse chow (Purina) and tap water ad 
libitum. The mice were kindly genotyped by Annette Gruber and Gitta Theide, at CBTM, 
Mannheim.  
 
2.8.1 β-galactosidase staining of embryos 
Embryos at appropriate stages were dissected and transferred immediately to a clean 
petri dish containing PBS, placed on ice. For early embryonic stages like E9.5 and 
E10.5, a light microscope was used to carry out the dissection process. Yolk sac and/or 
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embryonic tails were used for genotyping. Each dissected embryo was then placed in 
individual wells of a 24-well plate containing PBS, also kept on ice. The embryos were 
fixed in 4% PFA at room temperature, with gentle shaking for 1 hour (early stage 
embryos) or 2 hours (late stage embryos), after which they were washed with detergent 
containing wash buffer three times, 20 minutes each, also at room temperature and with 
constant gentle shaking. X-gal was added freshly to the staining solution, taking care 
not to expose it to light. After the final wash, staining solution was added to the embryos 
and it was ensured that they were covered in the staining solution. They were incubated 
at 37°C overnight. The following day, Asap1+/+, Asap+/GT and Asap1GT/GT embryos could 
be identified respectively on the basis of no stain, weak blue stain and intense blue 
stain. Where possible, phenotypes were confirmed by PCR. 
 
Reagent Concentration 
Wash buffer 
Disodium hydrogen phosphate pH 7.3 100 mM 
Sodium dihydrogen phosphate pH 7.3 100 mM 
Magnesium chloride 2 mM 
Sodium deoxycholate 0.10% 
Nonidet P-40 0.02% 
BSA 0.05% 
Staining solution 
Potassium ferricyanide (K3Fe(CN)6) 5 mM 
Potassium ferrocyanide (K4Fe(CN)6) 5 mM 
Sodium chloride 7.2 mM 
X-gal (reconstituted in DMF at 50 
mg/ml; added freshly) 0.3 mg/ml 
 
 
2.8.2 Genotyping of Asap1 mice 
Genotyping of Asap1 mice was performed by PCR amplification of genomic DNA 
extracted from either mouse tails or yolk sac (in case of embryos). Tails (or yolk sac) 
were lysed overnight in 400 µl of SNET buffer for genomic dna isolation and 10 µl of 
proteinase K at 55 °C, with light shaking at 750 rpm. The next day, the tubes were 
centrifuged at 13000 rpm for 10 minutes at RT. Supernatant (350 µl) was transferred 
into a fresh Eppendorf tube and 250 µl isopropanol was added and incubated at RT for 
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10 minutes. Tubes were centrifuged at 13000 rpm for 15 minutes, after which the 
supernatant was discarded. The pellet was air dried, and then 100 µl dd-water was 
added to it. PCR to assess the genotype was set up as given below. 
 
Reagent Concentration 
PCR setup 
DreamTaq Buffer (10x) 2.5 µl 
dNTPs 10 mM 0.5 µl 
Primer ASAPgeneTrap3’ for (10 µM) 1 µl 
Primer ASAPgeneTrap3’ rev (10 µM) 1 µl 
PrimerASAPgenomic5 for (10 µM) 1 µl 
Template (DNA) 2 µl 
Taq polymerase 0.1 µl 
dd-water 16.9 µl 
 
After preparing all the PCR samples on ice, these were put directly into the cycler with 
the following program. 
95	°C  2 min    
95	°C  1 min 
59	°C  1 min 33x 
72	°C  1 min 
72	°C  5 min  
   
The amplified DNA was stored at 4 °C and was electrophoresed using TAE agarose gel 
electrophoresis. Agarose (1% (w/v)) was dissolved in TAE buffer by heating. Ethidium 
bromide (0.2 µg/ml) was added before pouring the solution into a casting tray. Samples 
were mixed with 6x DNA loading dye, and the gel was run with 3-6 V/cm. A 1 Kb DNA-
ladder was used for size reference, and Asap1 heterozygous, Asap1 knockout and wild-
type along with water control was also run. DNA was visualized under UV-light.  
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  Wild-type (Asap1+/+) 
Heterozygous 
(Asap1+/GT) 
Knockout 
(Asap1GT/GT) 
Expected 
band sizes 330 bp 330 bp + 680 bp 680 bp 
 
 
 
 
Figure 9. Genotyping Asap1 mice. 
Chromosome 15 of a wild-type mouse where AsapGenomic5for and AsapGeneTrap3rev 
primers bind and upon polymerase chain reaction, produce an amplicon of 330 bp. (B) 
Asap1GT/GT allele with gene trap inserted into intron 2, as determined by genomic sequencing, 
and which contains complimentary sequence for AsapGeneTrap3for primer to bind and amplify, 
along with AsapGeneTrap3rev primer. The primer pair AsapGeneTrap3for and 
AsapGeneTrap3rev produce an amplicon of 680 bp. Heterozygous Asap1 mouse DNA 
produces two bands of 330 bp and 680 bp each.  
 
 
2.8.3 Alcian blue/Alizarin red staining of Asap1 embryos 
Asap1 embryos at specific stages (E15.5, E18.5) were obtained following cesarean 
section. The embryos were scalded in hot tap water (about 70 °C) for 20-30 sec, and 
their skin was removed carefully with the help of forceps. Internal organs were removed 
from the embryos so as to obtain their skeletons. These were then fixed in 95% ethanol 
overnight at RT. The next day, these mice were put in acetone and incubated overnight 
at RT. After briefly rinsing the mice with deionized water, they were stained for cartilage 
with alcian blue for 24 h. Next, the mice were washed in 70% ethanol for 6-8 h and then 
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transferred to 1% KOH overnight. Once the tissues were visibly cleared, they 
counterstained with alizarin red to stain their bone. The samples were cleared in 1% 
KOH/20% glycerol and stored in 1:1 glycerol: ethanol solution.  
 
2.8.4 Respiratory and growth parameters measurements 
Respiratory rate measurement 
Pups from a litter, when taken out of the cage for analysis, were kept together on a wad 
of tissues and placed on a metallic plate maintained at room temperature. This was 
done to keep the pups warm and comfortable thereby reducing any stress induced by 
the analysis. Pups were monitored one by one and the respiratory rate per minute per 
pup was recorded. Three measurements were made per pup and the average 
respiratory rate was calculated and used for analysis. Care was taken that the pups 
were returned to their mother as soon as possible to minimize stress.  
 
Size and weight measurement  
Embryos at appropriate stages (E17.5, E18.5) were dissected and transferred to a clean 
petri dish containing PBS, placed on ice. Yolk sac and/or embryonic tails were used for 
genotyping. With clean forceps, individual embryos were picked up and placed on a 
tissue paper. Using a ruler, head to base of the tail of embryos were measured.  
Pups were measured the same way, from head to base of the tail. Weight was 
measured by placing individual pups in a clean petri dish kept on a tabletop balance.  
 
2.8.5 Retinal whole-mount staining 
Asap1+/+ and Asap1GT/GT pups at specified postnatal age (P3-P7) were sacrificed and 
their eyeballs were carefully dissected out and fixed in ice cold 100% methanol. Retinas 
were then isolated and blocked in 0.5% Triton X-100/1% BSA for 1h at room 
temperature. FITC-conjugated Isolectin B-4 antibody was used to stain the retinas for 
1h at room temperature. Pictures were taken using a confocal microscope (Zeiss 
LSM710) and images were analyzed with Fiji, ImageJ. Relative angiogenesis was 
reported as stained area of the vasculature (Isolectin B-4+ area) compared to the total 
retinal area. Values obtained per animal were normalized to the mean value of the 
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Asap1+/+ pups. These experiments were performed in cooperation with the laboratory of 
Prof. Dr. Hellmut Augustin. 
 
2.8.6 Tumor development studies 
FVB, MMTV-PyMT and FVB, MMTV-Wnt1 – wild-type and Asap1GT/GT were used to 
study tumor development. Once mice developed spontaneous mammary tumors, the 
tumors were measured weekly. Mice were sacrificed either when the tumor reached 2 
cm in one direction or when the animals became moribund. After the animals were 
sacrificed by cervical dislocation, important parameters like the age, number of lesions 
and tumor volume (calculated using the formula, V= 4/3 x π x r3) were recorded, where r 
denotes the average radius of the tumor. Primary mammary tumors were either snap 
frozen or formalin-fixed, or were utilized immediately to isolate tumor-cells.  
 
2.8.7 Metastasis studies 
Lungs from FVB, MMTV-PyMT and FVB, MMTV-Wnt1 – wild-type and Asap1GT/GT mice 
were isolated after the primary tumor characteristics were recorded, and samples from 
the tumor tissue were prepared. Visible metastatic foci were counted on the lung 
surface, from all the lung lobes. The lungs were also studied under a light microscope to 
check for smaller metastatic foci that could not be observed by eye. Lungs were then 
either snap frozen or formalin-fixed for detailed analysis.  
 
2.8.8 Lung float analysis 
Pups at P0 were sacrificed by dislocating the head from the body through cutting at the 
base of the skull. Lungs were isolated, carefully removed with clean forceps, and placed 
in a glass test tube containing PBS. A healthy inflated lung floated on the solutions 
whereas a defective non-inflated lung sank to the bottom of the tube.  
 
2.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism v7. Data are expressed as 
mean ± s.d, unless stated otherwise. Statistical significance was calculated using either 
two-tailed paired Student’s t-test, ANOVA when comparing multiple groups followed by 
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Bonferroni’s comparison, or the Mann-Whitney’s U test for non-parametric data, and 
regression analysis for survival curves. In each case, the specific statistical test used is 
specified. A p-value of less than 0.05 was considered statistically significant, and is 
represented as * when p ≤ 0.05, ** when p ≤ 0.01 and *** when p ≤ 0.001.  
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3. Results 
 
My objectives in this study were to characterize the phenotype of Asap1 knockout mice, 
and to use them to investigate the role of Asap1 in tumor metastasis by crossing them 
with autochthonous murine breast cancer models 
 
3.1 Identification of Asap1 knockout embryos 
 
The Asap1GT/GT mice do not express endogenous Asap1 because of the loss-of-function 
mutation arising in the Asap1 gene from the gene trap. They do however, display lacZ 
fusion gene activity that enables an easy and sensitive method for detecting 
homozygous knockout progeny. This detection method relies on the ability of the 
embryos to cleave a compound known as X-gal into an insoluble blue-colored product 
that is detectable by eye. Homozygous wild-type (Asap1+/+) embryos appear colourless, 
homozygous knockout (Asap1GT/GT) mice develop an intense blue color, while the 
heterozygous embryos (Asap1+/GT) display a weak blue stain (Figure 10). Yolk sac from 
the embryos obtained by cesarean sections was utilized for genotyping to further 
validate correct identification. Once Asap1GT/GT mice were generated, the next task was 
to determine if Asap1 was dispensable for embryonic development of the mice and 
which embryonic growth processes were affected by its absence. 
 
 
 
Figure 10. Identification of Asap1 knockout embryos. 
X-gal staining performed on embryos obtained at various embryonic stages like E11.5 (A, D), 
E12.5 (B, E) and E13.5 (C, F) reveals homozygous Asap1 knockout (A, B, C) and heterozygous 
(D, E, F) embryos. 
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3.2 Deletion of Asap1 is partially neonatal lethal 
 
Adult Asap1GT/GT mice do not display any overt phenotypic differences when compared 
to wild-type mice. They are able to live to maturity and reproduce normally. The 
absence of a distinguishable phenotype does not however, hold true for Asap1GT/GT 
embryos and newborn pups. A careful study of 256 embryos and 176 newborn pups 
born from breeding heterozygous Asap1 mice, disclosed a strong, albeit transitory 
phenotype. Genotyping Asap1 embryos from various stages of gestation and on the day 
of their birth, P0, exhibited a disparity in the Mendelian ratio of homozygous Asap1 
knockout offspring (Figure 11 A). Normally when heterozygous transgenic mice are 
bred, the typical ratio of resultant homozygous wild-type, heterozygous transgenic and 
homozygous knockout offspring is 25%, 50% and 25% respectively. The Asap1GT/GT 
mice population arising from crosses between Asap1+/GT mice is significantly lower than 
expected. I found that across all embryonic stages Asap1GT/GT embryos maintain the 
expected normal ratio, with the discrepancy in their number arising only at birth (Figure 
11 B, C). These data suggest that loss of Asap1 speaks for a partially penetrant 
neonatal lethality.  
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Figure 11. Partial neonatal lethality in Asap1GT/GT mice.  
(A) Embryonic stage-wise distribution of Asap1+/+, Asap1+/GT and Asap1GT/GT mice indicating the 
number of offspring of each genotype and the corresponding Mendelian ratio at that age. Pie 
charts show distribution of offspring resulting from breeding of heterozygous Asap1 mice.  
Normal distribution of embryos (B) and abnormally reduced Asap1GT/GT newborn pups (C) 
demonstrate partially penetrant neonatal lethality.  
 
 
The partial neonatal lethality warranted a detailed study of Asap1GT/GT newborn pups. 
According to the Phenotype Ontology Database resource, in a study of genotypes 
associated with lethality, 26% of genotypes were lethal perinatal. Hence, the time of 
death in these mutant mice provides an important platform on which to base further 
investigations. I therefore performed an extensive study on late stage Asap1GT/GT 
embryos and the newborns. 
 
3.3 Late stage Asap1GT/GT embryos are smaller than wild-type embryos 
 
In order to understand the partial Asap1 lethal neonatal phenotype, I analyzed the 
perinatal Asap1GT/GT progeny. Embryos from E17.5 and E18.5 stages were isolated and 
assessed for gross morphological defects and any other apparent anomalies. 
Asap1GT/GT E17.5 embryos were smaller in size than their wild-type counterparts, 
although this difference was not statistically significant (Figure 12 A). No visually striking 
differences were noted. At E18.5, Asap1GT/GT embryos were found to be significantly 
smaller than the wild-type embryos (Figure 12 B). Growth retardation in the embryos 
immediately prior to birth may be a critical factor that could compromise their survival.  
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Figure 12. Size distribution of late stage Asap1
+/+
, Asap1
+/GT 
and Asap1
GT/GT
 embryos.  
(A) Smaller, though not statistically significant sizes of Asap1
GT/GT
 embryos at E17.5. (n=31). (B) 
Statistically significant smaller Asap1
GT/GT
 embryos at E18.5. (n=37, p= 0.0285). Student’s 
unpaired t test used for p value calculation 
 
 
3.4 Asap1GT/GT neonates display bradypnea and growth retardation  
 
To investigate the partially penetrant death of Asap1GT/GT neonates, they were carefully 
observed for the first days following their birth. The number of neonates, their activity 
and general features were carefully recorded. Upon a thorough checking of the cages, 
many dead neonates were found, often times partially cannibalized. As expected, 
Asap1GT/GT neonates formed the majority of the dead population (56%). While Asap1+/GT 
constituted 33%, Asap1+/+ represented only 11% of the stillborn pups. This observation 
explains the reduced Mendelian ratio observed in the Asap1GT/GT newborns. Asap1GT/GT 
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pups that survived appeared normal. These pups displayed an intact, hydrated skin 
dismissing any possibility of loss of body fluids through broken epidermis, an important 
factor for survival. These pups were not subjected to abnormal nursing by the mother 
and they demonstrated normal suckling. Defects in suckling were discounted as there 
was evidence of milk in the stomach of all of the pups.  
 
Respiratory rates of the neonatal pups were analyzed, which revealed an inability of 
Asap1GT/GT neonates to breathe normally. The breathing rates of these pups averaged 
82 per minute as against 109 per minute of the wild-type pups (Figure 13 A). Asap1GT/GT 
pups also demonstrated an irregular, pulsated breathing. The normal breathing rhythm 
in these pups was broken by bouts of respiratory apnea that was followed by a few 
short and rapid inhalation and exhalation attempts.  
 
Consistent with the findings in late stage embryos, Asap1GT/GT pups were found to be 
severely growth retarded. Their size and weight were significantly lower than the wild-
type pups (Figure 13 B, C). While the mean size of a wild-type pup was found to be 2.68 
cm, that of an Asap1GT/GT pup was only 2.43 cm. Similarly, the mean weight of a wild-
type pup was 1.56 g as compared to 1.26 g for an Asap1GT/GT pup. It is important to 
mention here that all of the dead pups that were retrieved from the cages weighed less 
than 1 g. The differences in respiratory rates, size and weight of wild-type and 
Asap1GT/GT neonates were found to be statistically significant. Interestingly, the disparity 
in the breathing and weights of these pups was found to be gene dose-dependent, in 
that these defects also affected the heterozygous pups. In these pups, a single mutated 
allele of Asap1 was sufficient to lower the breathing rates and weights.  
 
Pups were monitored for six days after being born and their respiratory rates and growth 
parameters were routinely recorded. Once the pups had survived the initial 24 hours of 
birth, none of them were found dead. While the respiratory rates and sizes of the 
neonates varied greatly on P0, these parameters gradually became comparable by the 
third or fourth day after birth (Figure 14 A, B). A day after birth, the breathing pattern of 
surviving Asap1GT/GT pups became regular and rhythmic, and matched those of wild-
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type pups. The breathing rates increased for Asap1+/+, Asap1+/GT and Asap1GT/GT pups 
comparatively, and no difference between knockout and wild-type pups was 
subsequently observed. All pups grew in size and weight, displaying normal growth and 
development, and no differences regarding the growth of Asap1+/+, Asap1+/GT and 
Asap1GT/GT pups was observed (Figure 14). A more detailed analysis with higher 
number of animals would be required to obtain a statistically robust result. However, the 
absence of bradypnea and growth retardation after the first day of birth strongly 
underlines the transient nature of this phenotype.  
 
3.5 Lungs of Asap1GT/GT neonates show areas of insufficient aeration 
 
Deletion of Asap1 compromised not just the respiratory rates, but also the quality of 
breathing. The observed bradypnea in neonatal Asap1GT/GT pups prompted further 
functional analyses of lungs isolated from P0 pups to understand possible causes of this 
transient phenotype. Although Asap1GT/GT pups exhibited abnormal breathing for the 
first hours after birth, their survival after 24 hours was not affected by this defect. I 
therefore isolated lungs from early neonates and analyzed their aeration. To this end, 
lungs were tested for their ability to float on phosphate-buffered saline (PBS). Under 
these conditions, poorly aerated lungs sink, while healthy aerated lungs float. Compared 
to other genotypes, a significantly higher proportion of the Asap1GT/GT lungs sank, 
indicating abnormal aeration (Figure 15 A). Specifically, 45% of Asap1GT/GT lungs 
displayed inability to float as compared to 18% of Asap1+/+ and 24% of Asap1+/GT lungs 
that sank.  
 
To further investigate this phenotype, the lungs were embedded in paraffin, sectioned 
and stained to study their histology. This revealed why many of the Asap1GT/GT lungs 
could not float in PBS, as instead of a well-aerated parenchyma, many areas of thick 
mesh-like parenchyma were observed (Figure 15 B). These observations suggest that 
the bradypnea phenotype of Asap1GT/GT pups may be caused by an improperly 
developed lung parenchyma that limits aeration, possibly compounded by defective 
growth that may contribute to the severely impaired breathing in Asap1GT/GT pups.  
 57 
 
 
 
 
 
 
 
Figure 13. Respiratory rates 
and growth analysis of 
Asap1
+/+
, Asap1
+/GT 
and 
Asap1
GT/GT
 pups.  
Asap1
GT/GT
 pups (n=31) display 
reduced breathing rates (A), 
lower sizes (B) and lower 
weights (C) as compared to 
wild-type (n=56) and 
heterozygous (n=89) pups. p 
values for respiratory rates, 
sizes and weights are given 
with following comparison 
between wild-type versus 
heterozygous, knockout versus 
heterozygous and wild-type 
versus knockout, respectively 
(Respiratory rates p=0.38, 
0.001, 6.1x10
-5
; Sizes p=0.01, 
0.06, 9.3x10
-5
; Weights p=0.03, 
9.12x10
-5
, 1.9x10
-8
). Student’s 
unpaired t test used for p value 
calculation. 
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Figure 14. Time course 
analysis of Asap1
+/+
, 
Asap1
+/GT 
and Asap1
GT/GT
 
pups.  
Pups were analyzed for 
respiratory rates (A), sizes 
(B) and weights (C).  
Values for breathing rates 
and growth parameters 
consistently increase 
every post-natal day and 
Asap1
GT/GT
 pups (n=3) 
record values comparable 
to both Asap1
+/+
 (n=4) and 
Asap1
+/GT
 (n=12) pups 
after P0.  
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Of interest is also the fact that 11% of Asap1+/+ pups were found dead at birth. 
Consistently, 18% of Asap1+/+ neonatal lungs were inadequately aerated, as assessed 
by their inability to float in PBS. Thus wild-type pups can exhibit similar defects to 
Asap1GT/GT pups, albeit at a statistically significant lower frequency.  
 
 
 
Figure 15. Functional analyses of Asap1+/+ and Asap1GT/GT lungs.  
Lung float test (A) shows that majority of Asap1GT/GT lungs (n=8) cannot float in PBS as 
compared to Asap1+/GT (n=15) and Asap1+/+ (n=16) lungs. (p=0.0007, fisher test). H&E stained 
Asap1GT/GT (B) and Asap1+/+ (C) lungs showing histology. Arrows indicate poorly aerated areas 
of lung.  
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3.6 Asap1 deficiency delays neonatal retinal angiogenesis  
 
Endothelial cells express high levels of ASAP1, and VEGFR2 promotes angiogenesis 
by activating a pathway involving ASAP1 (Hashimoto et al., 2011). Furthermore, ASAP1 
regulates cell motility, a key cellular process during angiogenesis. I therefore 
hypothesized that ASAP1 may play a role in angiogenesis. To explore this hypothesis, I 
investigated retinal angiogenesis in Asap1+/+ and Asap1GT/GT mice. To this end, retinas 
of Asap1+/+ and Asap1GT/GT pups were isolated at various post-natal days, starting from 
P3, and stained to study vascular network development. For technical reasons, it was 
difficult to carry out retinal angiogenesis analyses on younger pups (P0, P1 and P2) 
because the retinas from these pups were extremely fragile, and the outgrowth of the 
retina was sub-optimal for quantification. The Asap1GT/GT retinas showed reduced retinal 
angiogenesis until P5, after which they display angiogenesis comparable with that in 
Asap1+/+ retinas (Figure 16). The initial delay in the outgrowth of retinal vascular network 
in Asap1GT/GT retinas is transient, and only lasts until about P5, after which normal 
retinal angiogenesis was observed. Although the differences in the quantified retinal 
angiogenesis are not statistically significant, there is nevertheless a tendency of delayed 
retinal vascularization in the absence of Asap1.  
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Figure 16. Retinal angiogenesis in Asap1+/+ and Asap1GT/GT pups.  
(A) Quantification of retinal angiogenesis through P3-P7 stages. P>0.05.  A delay in retinal 
angiogenesis is seen in P3 and P5 stages. (B, C, D) Stained retinas of Asap1+/+ and Asap1GT/GT 
at P3 (n=3, n=2), P5 (n=2, n=2) and P7 (n=3, n=4) are shown respectively. Experiment 
performed in collaboration with Dr. Claudia Korn, DKFZ, Heidelberg.  
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3.7 Asap1 does not influence lymphangiogenesis 
 
As there was a tendency for delayed development of the vasculature in retinas of 
Asap1GT/GT pups compared to Asap1+/+ pups, we investigated whether 
lymphangiogenesis is also affected by loss of Asap1. Consistent with this hypothesis, 
the thoracic duct was found to express Asap1 (Figure 17 A). Lymphatic ring assays 
were therefore performed with thoracic ducts isolated from 2-3 months old Asap1+/+ and 
Asap1GT/GT mice. In these ex-vivo lymphangiogenesis assays, pieces of thoracic duct 
were embedded in collagen and the outgrowth of lymphatic vessels was assessed. No 
difference in lymphangiogenesis between Asap1+/+ and Asap1GT/GT mice was observed. 
Asap1 plays no apparent role in lymphangiogenesis process, suggesting that this 
process does not rely on Asap1-mediated cellular motility, or that other molecules may 
be compensating for ASAP1.  
 
 
 
Figure 17. Lymphangiogenesis in Asap1+/+ and Asap1GT/GT mice.  
(A) Asap1 expression in thoracic duct. (B) No significant difference between Asap1+/+ and 
Asap1GT/GT is observed in lymphatic vessel density (n=6, n=6, p=0.5) and (C) also in lymphatic 
ring assay (n=30, n=54, p=0.7). Experiments performed by Dr. Anja Schmaus, Dr. Melanie 
Rothley and Dr. Diana Plaumann, KIT, Karlsruhe. 
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3.8 Loss of Asap1 impairs ossification 
 
The growth retardation in Asap1GT/GT neonates, prompted us next to investigate whether 
Asap1 plays a role in bone development. Skeletons of E15.5 Asap1+/+ and Asap1GT/GT 
embryos were therefore prepared and stained with Alizarin Red and Alcian Blue to 
visualize bone and cartilage respectively (Figure 18). Clearly, Asap1GT/GT embryos show 
normal cartilage development. However, they show ossification defects. It is noteworthy 
that loss of Asap1 affects both types of ossification processes – the intramembranous 
as well the endochondral ossification. Lack of Alizarin Red staining in the skull bone and 
vertebrae indicate both modes of ossification are compromised in the absence of 
Asap1. This defect in ossification could conceivably predispose Asap1GT/GT embryos 
and neonates to delayed growth development.  
 
 
 
 
Figure 18. Impaired ossification in E15.5 Asap1GT/GT embryos.  
Normal cartilage development as seen by Alcian Blue staining and defective ossification as 
seen by Alizarin Red staining. Arrows indicate differences in ossification in Asap1+/+ and 
Asap1GT/GT embryos. Experiment performed together with Dr. Caroline Schreiber, CBTM, 
Mannheim.  
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Role of ASAP1 in breast cancer development and progression 
 
Given our own work and that of others showing that ASAP1 expression correlates with 
poor prognosis in human breast and colorectal cancer patients, I investigated the role of 
ASAP1 in breast cancer using three autochthonous mouse models, namely MMTV-Neu, 
MMTV-Wnt1 and MMTV-PyMT. To this end, heterozygous Asap1 mice were bred with 
these three mouse models that form spontaneous mammary tumors, and tumor 
development and metastasis in Asap1+/+- and Asap1GT/GT- tumor-bearing mice were 
monitored. 
 
3.9 Tumorigenesis in MMTV-Neu Asap1+/+ and MMTV-Neu Asap1GT/GT mice  
 
It was observed that Neu Asap1+/+ and Neu Asap1GT/GT mice presented with multifocal 
mammary tumors, formed after a long and highly varying latency period. The mice were 
sacrificed when the size of the tumor reached 2 cm in one dimension. The tumor burden 
at the time of sacrifice varied within the group, with most of the tumors being necrotic. 
Although the group size was too small to allow a statistical analysis, nevertheless there 
was no obvious difference in the size of the primary tumors from Neu Asap1+/+ and Neu 
Asap1GT/GT mice (Figure 19). Tumor necrosis did not positively correlate with the tumor 
size. Even small tumors were found to be necrotic or fluid-filled, making a detailed study 
of the primary tumor impossible. Lungs were isolated from these mice to study surface 
metastases, but no metastasis was recorded in any of the mice studied. Due to these 
problems, this murine model of breast cancer was discontinued for the purpose of 
elucidating the role of Asap1 in tumor development and metastasis.  
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Figure 19. Tumor volumes of MMTV-Neu Asap1+/+ and MMTV-Neu Asap1GT/GT mice.  
The MMTV-Neu Asap1+/+ (n=16) and MMTV-Neu Asap1GT/GT Mice (n=2) tumor mice display 
highly varying tumor burden at the time of sacrifice. Total tumor volume refers to the sum of the 
volumes of all the mammary tumors formed in the animal. 
 
 
3.10 Tumorigenesis in MMTV-Wnt Asap1+/+ and MMTV-Wnt Asap1GT/GT mice  
 
The Wnt Asap1+/+ and Wnt Asap1GT/GT mice developed tumors following a long and 
highly varying latency period, in that Wnt Asap1+/+ mice developed tumors only at 14 
weeks of age whereas Wnt Asap1GT/GT mice developed tumors at about 20 weeks of 
age, thus displaying a delayed tumor onset (Figure 20 A). The mice rarely, if ever 
presented with multifocal mammary tumors. They developed tumors only in any one of 
the mammary glands. Once palpable, tumors were routinely measured and growth 
curves were generated. I found that both groups of mice exhibited heterogeneous tumor 
growth patterns (Figure 20 B). It was thus difficult to draw conclusive remarks about the 
role of Asap1 in delaying tumor onset in this model of breast cancer as the tumors 
developed at varying ages, and no statistically significant difference in the age was 
found at the time of palpable tumor formation. The mice were sacrificed when the tumor 
reached 2 cm in one dimension. At the time of sacrifice, both groups of mice displayed 
comparable average tumor burden (Figure 20 C) and lungs were isolated from them to 
study metastases. However, I found no incidence of lung metastasis in any of the mice.  
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Figure 20. Tumor growth characteristics of MMTV-Wnt Asap1
 +/+
 and MMTV-Wnt 
Asap1
GT/GT
 Mice. (A) Tumor-free survival curves showing that MMTV-Wnt Asap1
 +/+
 mice (n=19) 
develop tumors earlier than MMTV-Wnt Asap1
GT/GT
 mice (n=9) at 14 weeks as compared to 20 
weeks. P>0.05. (B) Tumor growth curves showing highly variable growth characteristics of 
tumors formed in MMTV-Wnt Asap1
 +/+ 
and MMTV-Wnt Asap1
GT/GT
 mice. P>0.05. (C) The total 
tumor volume at the time of sacrifice is comparable in MMTV-Wnt Asap1
 +/+ 
and MMTV-Wnt 
Asap1
GT/GT
 mice. Total tumor volume refers to the sum of the volumes of all the mammary 
tumors formed in the animal. P>0.05. 
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	3.11 MMTV-PyMT Asap1GT/GT mice show early tumor onset and increased 
metastasis to lungs compared to MMTV-PyMT Asap1+/+ mice 
 
MMTV-PyMT Asap1+/+ and MMTV-PyMT Asap1GT/GT mice, like the two previously 
described mouse models, were studied for tumor growth and lung metastases. PyMT 
mice were analyzed either by me or by Dr. Caroline Schreiber. Analysis was matched/ 
aligned. It was found that PyMT Asap1GT/GT mice displayed a shorter tumor-free survival 
as compared to the wild-type mice, indicative of an early tumor onset in these mice 
(Figure 21 A). The median tumor-free survival for PyMT Asap1+/+ mice was 60 days 
whereas that for PyMT Asap1GT/GT mice was 52.5 days. The mice were sacrificed when 
the tumor reached 2 cm in one dimension. These mice developed multifocal mammary 
tumors and upon comparison of tumor volumes in the two groups of mice, it was found 
that PyMT Asap1GT/GT mice displayed significantly higher tumor volumes in the weeks 
immediately prior to their sacrifice. Hence, the tumors in the Asap1 knockout mice grew 
faster and more aggressively than the tumors in the PyMT Asap1+/+ mice (Figure 21 B).  
 
At weeks 10, 11 and 12 after palpable tumors were detected in PyMT Asap1+/+ and 
PyMT Asap1GT/GT mice, there was a significantly higher tumor burden in the PyMT 
Asap1GT/GT mice. However, between week 12 and 13, the tumors in PyMT Asap1+/+ 
mice grew in size such that the tumor burden in the two groups of mice became 
comparable.  
 
When the tumor volumes of PyMT Asap1+/+ tumors in the penultimate and final week 
before sacrifice (86-96 days) were plotted against time and linear regression analysis 
was performed, it was found that these tumors displayed a positive slope, indicating that 
tumor size positively correlated with age and that tumors increasingly grow in size 
(Figure 21 C), suggesting they are still in the exponential phase of growth. On the other 
hand, Asap1 knockout tumors displayed a negative slope when a similar analysis was 
performed, indicating that tumors have reached a plateau and tumor sizes no more 
positively correlate with age (Figure 21 D). This implies that Asap1GT/GT tumors grew 
faster and more aggressively, thereby reaching a plateau by roughly 90 days after the 
first palpable tumors were detected, whereas Asap1+/+ tumors grew more slowly, 
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exhibiting significantly lower tumor volumes than Asap1GT/GT tumors, and were still found 
to be growing exponentially at roughly 90 days when Asap1GT/GT tumors had already 
reached a plateau phase. Taken together, this means that deletion of Asap1 results in 
faster growing tumors in the PyMT mouse model. 
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Figure 21. Tumor growth characteristics of MMTV-PyMT Asap1
+/+
 and MMTV-PyMT 
Asap1
GT/GT
 Mice.	 (A) Tumor-free survival curves showing that MMTV-PyMT Asap1
GT/GT
 mice 
(n=19) develop tumors earlier than MMTV-PyMT Asap1
+/+
 mice (n=16) at 52.5 days as 
compared to 60 days. P>0.05. (B) Tumor growth curves showing that PyMT Asap1
GT/GT
 mice 
bear significantly higher volumes of tumor at week 10 (p=0.0061), week 11 (0.0036) and week 
12 (0.0133) as compared to PyMT Asap1
+/+
 mice. The dotted boxes at week 13 display tumor 
growth as depicted by linear regression analysis that reveals exponential growth phase of PyMT 
Asap1
+/+
 tumors (C) and plateau phase of PyMT Asap1
GT/GT
 tumors (D). 
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The PyMT Asap1+/+ and PyMT Asap1GT/GT mice formed tumors with short latency 
periods and high penetrance. Nevertheless, they exhibited a comparable mean tumor 
burden when lungs were isolated from them for the purpose of analysing metastasis 
formation (Figure 22 A). It was found that PyMT Asap1GT/GT lungs contained significantly 
higher number of superficial metastatic foci on the lung surface as compared to PyMT 
Asap1+/+lungs (Figure 22 B). Lungs from these mice were embedded in paraffin, 
sectioned and stained using hematoxylin and eosin to study micrometastases. A total of 
10 sections (5 µm thick), 100 µm apart were selected. The number of deep metastatic 
lesions was counted and it was found that PyMT Asap1GT/GT lungs again showed higher 
number of metastases (Figure 22 C) and larger metastatic foci size (Figure 22 D). 
Although this difference was not found to be statistically significant, the trend is similar 
to the surface metastasis count.  
 
Given that PyMT Asap1GT/GT mice formed tumors earlier than PyMT Asap1+/+ mice, it is 
reasonable to argue that Asap1 knockout tumors can colonize the lung earlier than 
Asap1+/+ tumors. Furthermore, the metastatic foci formed by Asap1+/+ tumors were 
fewer in number and smaller in size than those formed by Asap1GT/GT tumors. Together 
the data from the metastasis study shows that absence of Asap1 confers an enhanced 
metastatic potential on the primary mammary tumor in the PyMT model of breast 
cancer.  
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Figure 22. Metastasis study in MMTV-PyMT Asap1 +/+ and MMTV-PyMT Asap1GT/GT mice.  
(A) PyMT Asap1+/+ and PyMT Asap1GT/GT mice display comparable total tumor volumes when 
lungs were isolated from them for metastasis studies. Total tumor volume refers to the sum of 
the volumes of all the mammary tumors formed in the animal. (B) Surface metastases as 
counted on the lung lobes of the mice show that PyMT Asap1GT/GT mice have significantly higher 
metastases (p=0.0021) as compared to PyMT Asap1+/+ mice. Deep metastasis count as 
obtained from sectioning the lungs and counting the metastasis reveals a similar trend as that of 
surface metastasis and shows that PyMT Asap1GT/GT mice have more number (C) and bigger 
(D) metastasis than PyMT Asap1+/+ mice, although the difference was not statistically 
significant. (E) shows H&E stained images of PyMT Asap1+/+ and PyMT Asap1GT/GT lungs. 
Arrows indicate metastatic foci. 
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3.12 Morphological and molecular analysis of tumors from MMTV-PyMT 
Asap1GT/GT and MMTV-PyMT Asap1+/+ mice 
 
To determine whether deletion of Asap1 leads to modification of tumor subtype, tissue 
of cancer origin, or other characteristics of the primary and metastatic tumors, tumors 
from PyMT Asap1+/+ and PyMT Asap1GT/GT mice were isolated and formalin-fixed. 
Sections were stained with hematoxylin and eosin, and also used for 
immunohistochemistry. As normal breast tissue is composed of three types of cells – 
luminal, basal and myoepithelial – antibodies against markers of these cell types were 
used. Luminal cells express cytokeratins (CK) 7, 8, 18, 19, estrogen receptor (ER) and 
progesterone receptor (PR). Basal cells express CK 5/6, 14, 17. Myoepithelial cells 
express basal cell-type CKs and other markers like smooth muscle actin ((Böcker et al., 
1992). The tumor sections obtained from PyMT Asap1+/+ and PyMT Asap1GT/GT mice 
were therefore stained with antibodies against luminal (CK18), basal (CK14) and 
myoepithelial (smooth muscle actin) markers. The staining revealed that tumors from 
both PyMT Asap1+/+ and the PyMT Asap1GT/GT mice stained for luminal cytokeratin as 
well as basal cytokeratin. The staining confirmed the epithelial origin of the tumors.  
 
In the normal breast, the interstitial fibroblasts do not express a-smooth muscle actin 
(SMA) whereas peritumoral stromal myofibroblasts in breast carcinoma have been 
shown to express this protein ((Rønnov-Jessen et al., 1995). SMA staining is therefore 
used as a marker for activated stromal fibroblasts. It was found that PyMT Asap1GT/GT 
mice displayed a more intense SMA staining (Figure 23), suggesting that differences 
exist in the tumor stroma in PyMT Asap1GT/GT mammary tumors compared to PyMT 
Asap1+/+ tumors.  
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Figure 23. Immunohistochemistry of PyMT Asap1+/+ and PyMT Asap1GT/GT tumors 
showing the epithelial nature of the mammary tumors. Cytokeratin staining (CK14) reveals 
a concomitant expression of basal subtype (A) and a luminal (CK18) subtype (B) of breast 
tumor. SMA staining (C) reveals a reactive stroma in PyMT Asap1GT/GT tumors. Immunostaining 
was achieved using specified antibodies and NovaRed (red/brown color) and tissues were 
counterstained with hematoxylin (blue color).  
 
 
3.13 Properties of tumor cells derived from tumors of MMTV-PyMT Asap1GT/GT and 
MMTV-PyMT Asap1+/+ mice 
 
3.13.1 Cell migration and adhesion assays 
 
To investigate in more detail how loss of ASAP1 modified tumor growth and metastasis, 
I isolated tumor cells from PyMT Asap1+/+ and PyMT Asap1GT/GT tumors and established 
them in culture. I also isolated embryonic fibroblasts from Asap1+/+ and Asap1GT/GT 
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mice, and used these cells as positive controls to study the processes of cell migration 
and adhesion. 
 
As ASAP1 has been implicated in regulating cell migration, wound-healing migration 
assays were performed, in which cultured monolayers of Asap1+/+and Asap1GT/GT 
fibroblasts and PyMT Asap1+/+and Asap1GT/GT tumor cells were wounded and allowed to 
heal over a period of time. In comparison to Asap1+/+ fibroblasts, Asap1GT/GT fibroblasts 
showed significantly reduced cell migration 6,12 and 18 hours after monolayer 
wounding. This effect was quantified as percent wound-healing. Whereas Asap1+/+ 
fibroblasts display complete wound closure at 18 hours, Asap1GT//GT fibroblasts are only 
able to close 46.9% of the wound area at this time-point (Figure 24 A, B). In contrast, 
PyMT Asap1+/+ and PyMT Asap1GT/GT tumor cells displayed comparable cell migration, 
as PyMT Asap1+/+ tumor cells closed 55% and PyMT Asap1GT/GT tumor cells closed 
65% of the wounded area 24 hours after creation of the wound (Figure 24 C, D).  
 
To study adhesion defects, a spreading assay was performed in which cells were 
seeded on a fibronectin-coated plate and fixed at certain time intervals. The percentage 
of attached cells was determined. At 40 minutes post seeding, it was found that 66.25% 
Asap1+/+ fibroblasts attached to the substratum as compared to 57.52% Asap1GT//GT 
fibroblasts (Figure 24 E, F).  No statistically significant adhesion differences were 
observed between PyMT Asap1+/+ and PyMT Asap1GT/GT tumor cells as comparable 
percentage of cells from wild-type and Asap1 knockout tumors – 57.75% and 54.75%, 
respectively, were found to attach to fibronectin-coated plates at 1 hour of seeding 
(Figure 24 G, H).  
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Figure 24. Cell migration and spreading assay in Asap1+/+ and Asap1GT/GT fibroblasts and 
PyMT Asap1+/+and Asap1GT/GT tumor cells. Asap1GT/GT fibroblasts show significantly reduced 
cell migration (p<0.001) as compared to Asap1+/+ fibroblasts (A). Images of fibroblasts at 0h and 
18h are shown (B). PyMT Asap1+/+ and PyMT Asap1GT/GT tumor cells display comparable 
migration behavior (C). Images at 0h and 24h are shown (D). Asap1GT/GT fibroblasts show 
significantly reduced cell adhesion on fibronectin at 40 minutes after plating (p<0.001) (E). 
Images for Asap1+/+ and Asap1GT/GT fibroblasts at this time point are shown (F). PyMT 
Asap1+/+and Asap1GT/GT tumor cells do not display any cell adhesion differences (G). Images at 
1h are shown for tumor cells.  
 
 
3.13.2 Studying the actin cytoskeleton 
 
Specific cellular machineries are known to be involved in enabling motility. Having 
observed migration and adhesion defects in Asap1GT/GT fibroblasts, I next investigated 
whether proteins associated with motility-enabling structures were affected by the 
absence of ASAP1. When stained for ASAP1, Asap1GT/GT fibroblasts and PyMT 
Asap1GT/GT tumor cells showed no expression of ASAP1, thus confirming the deletion of 
Asap1 (Figure 25 B, D). In Asap1+/+ fibroblasts and PyMT Asap1+/+ tumor cells, ASAP1 
showed cytoplasmic and perinuclear localization (Figure 25 A, C). Actin fibers did not 
exhibit any striking visual difference in the absence of ASAP1. 
 
ASAP1 has previously been shown to colocalize with several focal adhesion markers 
such as b1 integrin, paxillin, FAK and vinculin. Hence, I hypothesized that focal 
adhesion assembly may be perturbed in the absence of Asap1. To test this possibility, I 
stained Asap1+/+ and Asap1GT/GT fibroblasts and PyMT Asap1+/+and Asap1GT/GT tumor 
cells with vinculin and actin so as to analyze focal adhesions and actin fibers in these 
cells. Asap1+/+ fibroblasts showed a more intense vinculin staining as compared to 
Asap1GT/GT fibroblasts (Figure 26 A, C). Stress fiber formation was not affected by the 
loss of Asap1, as visually no differences were observed in the actin stress fibers formed 
by Asap1+/+ and Asap1GT/GT fibroblasts (Figure 25 A, B and Figure 26 A, C). PyMT 
Asap1+/+ cells showed very specific vinculin staining at the periphery so that distinct 
focal adhesions were visible at the cell edge. In contrast, PyMT Asap1GT/GT cells 
showed an increased, yet random arrangement of focal adhesions throughout the 
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cytoplasm and little staining at the periphery, implying a less efficient ability to organize 
and/or traffic cytoskeletal and focal adhesion proteins (Figure 26 E, G).  
 
 
 
Figure 25. Actin cytoskeleton in Asap1+/+ and Asap1GT/GT fibroblasts and PyMT 
Asap1+/+and Asap1GT/GT tumor cells. Loss of Asap1 does not affect actin framework in 
fibroblasts and tumor cells derived from PyMT mice. ASAP1 staining confirms its cytoplasmic 
and perinuclear localization (A, C). No ASAP1 staining was observed in Asap1GT/GT fibroblasts 
(B) and PyMT Asap1GT/GT tumor cells (D), showing deletion of Asap1 in these cells.  
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Figure 26. Inefficient focal adhesion assembly in Asap1GT/GT fibroblasts and PyMT 
Asap1GT/GT tumor cells. Asap1+/+ fibroblasts display a more intense staining for vinculin, a focal 
adhesion marker (A, B) as compared to Asap1GT/GT fibroblasts (C, D) and PyMT Asap1+/+ tumor 
cells show extremely specific vinculin staining that display organized peripheral focal adhesions 
(E, F) as against PyMT Asap1GT/GT tumor cells that exhibit an increased, yet randomly arranged 
focal adhesions (G, H). These results demonstrate defective focal adhesion assembly in the 
absence of Asap1. Black and white images (B, F, D, and H) show intense and specific vinculin 
staining. 
 
 
 
 
Figure 27. Inefficient remodeling of actin in Asap1GT/GT fibroblasts upon EGF stimulation. 
The resting phenotype of fibroblasts undergoes a change when the cells are stimulated to 
move, in response to EGF. Asap1+/+ fibroblasts display a strong expression of nuclear actin 
after 20 minutes of EGF treatment thus showing that they are able to remodel their actin 
framework as opposed to Asap1GT/GT fibroblasts, which do not change their resting phenotype 
after addition of EGF. The expression of nuclear actin is temporary, after cells return to their 
original resting states.  
 
 
The results obtained are indicative of a perturbed actin cytoskeleton in Asap1GT/GT 
fibroblasts, as demonstrated by their reduced cell migration, reduced cell spreading and 
disorganized focal adhesion assembly. Next, I therefore decided to study the 
cytoskeleton of these cells in response to a migratory stimulus, namely epidermal 
growth factor (EGF). When cells were treated with EGF and monitored over the 
- EGF + EGF 20 mins + EGF 60 mins 
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specified time periods, it was found that Asap1+/+ fibroblasts exhibited an accumulation 
of actin in their nuclei. The nuclear actin was visible 20 minutes after the addition of 
EGF to the cells and remained until about 50 minutes after EGF addition, after which 
the resting phenotype of the cell was restored. In the case of Asap1GT/GT fibroblasts, no 
such remodeling of actin was observed until much later time points (data for later time-
points not shown), indicating that actin remodeling is impaired in Asap1 deficient 
fibroblasts (Figure 27).  
 
3.14 Studying the effects of ASAP1-SLK interactions  
 
In line with the observations pertaining to the role of Asap1 in regulating the actin 
cytoskeleton, certain interaction partners of ASAP1, like c-src, SLK and cortactin have 
been documented to functionally contribute towards podosome formation and adhesion 
structures that are typically formed in migrating cells that facilitate processes of invasion 
and matrix remodeling ((Brown et al., 1998; Onodera et al., 2005; Wagner et al., 2002). 
One of these interaction partners, Ste20-like kinase (SLK) was shown to co-
immunoprecipitate with ASAP1 ((Müller et al., 2010) and I chose to study how the 
interaction of ASAP1 with SLK might influence the actin cytoskeleton. For this, I 
stimulated the Asap1+/+ and Asap1GT/GT fibroblasts to move by wounding cell 
monolayers, and then stained these cells for specific markers of cytoskeletal proteins 
and focal adhesions. In mouse fibroblasts, SLK has been shown to colocalize with the 
microtubule network and peripheral focal adhesions as reflected by a-tubulin and 
vinculin staining ((Wagner et al., 2002). I therefore investigated whether the interaction 
of SLK with the cytoskeleton and focal adhesions is influenced by ASAP1. After 
monolayer wounding and subsequent healing, Asap1+/+ and Asap1GT/GT fibroblasts were 
stained with SLK and actin antibodies. SLK did not co-localize with actin, irrespective of 
ASAP1 expression (Figure 28 A, D and G, J). 
 
An increase in tubulin staining was observed in Asap1+/+ fibroblasts, 12 hours post-
wounding. In Asap1GT/GT fibroblasts, however, tubulin expression remained unchanged 
(Figure 28 B, E and H, K). Vinculin expression increased in Asap1+/+ fibroblasts 12 
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hours after cells were stimulated to move by wounding their monolayer. In contrast, 
Asap1GT/GT fibroblasts displayed unchanged vinculin expression (Figure 28 C, F and I, 
L).  
 
 
 
Figure 28. Effects of SLK on cytoskeleton and focal adhesion in Asap1+/+ and Asap1GT/GT 
fibroblasts. When the cells were stimulated to move, by wounding their monolayers and letting 
them heal, SLK did not colocalize with actin (A, D, G, J); tubulin expression increased in 
Asap1+/+ fibroblasts (E) but not in Asap1GT/GT fibroblasts (K); increased vinculin expression 
observed in Asap1+/+ fibroblasts (F) but not in Asap1GT/GT fibroblasts (L). Respective control 
images at 0h are also shown (A, B, C, G, H, I).   
 
 
After having studied the role of SLK on the expression of tubulin and vinculin, I next 
explored whether ASAP1 affected the expression of SLK, and for this Asap1+/+ and 
Asap1GT/GT fibroblasts were stained with SLK. It was observed that Asap1GT/GT 
fibroblasts exhibited reduced SLK staining as compared to Asap1+/+ fibroblasts (Figure 
29 A). This effect was quantified and indeed, SLK expression was found to be 
significantly reduced in Asap1GT/GT fibroblasts (Figure 29 B). The decline in SLK 
expression was also assessed by immunoblotting and I observed that SLK expression 
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was drastically reduced in Asap1GT/GT fibroblasts (Figure 29 C). In another experiment 
(performed by Katharina Fibi, data not shown), it was found that SLK transcript levels 
were not altered in Asap1+/+ and Asap1GT/GT fibroblasts. This implies that Asap1+/+ and 
Asap1GT/GT fibroblasts express similar levels of SLK mRNA, however there is a 
significant reduction in the protein levels of SLK in Asap1GT/GT fibroblasts, suggesting a 
role for ASAP1 in stabilizing the SLK protein.  
 
Next, I checked whether ASAP1 colocalizes with SLK, with which it also co-
immunoprecipitates. However, I found that these two proteins exhibit distinct subcellular 
localizations and do not colocalize (Figure 29 D). I studied the expression of SLK in the 
tumors obtained from PyMT Asap1+/+ and PyMT Asap1GT/GT mice, and found that the 
reduction of SLK expression in the absence of ASAP1 was also reflected in the tumors, 
and that PyMT Asap1GT/GT tumors displayed reduced SLK staining as compared to 
PyMT Asap1+/+ tumors (Figure 29 E).  
 
Taken together, the data suggest that in the absence of ASAP1, mouse fibroblasts have 
an impaired ability to reorganize actin cytoskeleton and focal adhesion assembly, 
leading to reduced cell migration and spreading on fibronectin. Protein expression of 
SLK, but not SLK mRNA, was also severely reduced in the absence of ASAP1, implying 
that ASAP1 is an important factor to maintain the stability of SLK. 
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Figure 29. ASAP1-SLK interactions. Reduced SLK expression in Asap1GT/GT fibroblasts (A) 
and quantification of this effect (B) that shows significant reduction (p<0.001) of SLK+ cells in 
Asap1 deficient fibroblasts. SLK protein levels, as seen by immunoblotting, are also reduced in 
Asap1GT/GT fibroblasts (C). ASAP1 (red) and SLK (green) do not colocalize (D). Tumors obtained 
from PyMT Asap1+/+ and PyMT Asap1GT/GT mice, stained for SLK show decreased SLK 
expression in PyMT Asap1GT/GT tumors (E). Tissues were stained with SLK antibody and 
NovaRed (red/brown color) and counterstained with hematoxylin (blue color). 
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4. Discussion 
 
Previous work in the Sleeman lab has shown that Asap1 is functionally involved in the 
process of metastasis, and consistently is correlated with poor prognosis of colorectal 
cancer patients. During my thesis work, my aim was to decipher normal physiological 
roles for Asap1 as well as to understand its function in the cancer context. To this end, I 
worked with mice with targeted deletion of Asap1. Deletion of Asap1 results in partially 
penetrant neonatal lethality. The surviving pups manifest Asap1 deficiency in the form of 
severe growth retardation and respiratory distress. Angiogenesis is reduced in the 
absence of Asap1. Using autochthonous models of breast cancer, I studied breast 
tumor development and metastasis in mice harboring global deletion of Asap1. The 
phenotype associated with the loss of Asap1 in murine models of breast cancer is a 
shorter tumor-free survival, more aggressive tumor growth and higher numbers of 
metastases.  
 
4.1 Mouse phenotype in the absence of Asap1 
 
4.1.1 Growth retardation and respiratory distress 
 
Adult Asap1GT/GT mice do not display any overt phenotype and are morphologically 
undistinguishable from wildtype mice. However, Asap1GT/GT mice display a disparity in 
the Mendelian ratio of offspring born from Asap+/GT mice breeding, in that, the number of 
homozygous Asap1 knockout survivors is drastically reduced at birth. Two prominent 
features pertaining to Asap1GT/GT neonates are revealed upon their birth. First, many 
Asap1GT/GT neonates are found dead at birth, and secondly, the surviving neonates are 
growth retarded and display significantly reduced breathing rates, a phenomenon 
known as bradypnea. For a newborn pup, the first extrauterine challenge is to be able to 
breathe, and defects in multiple physiological systems could work to interfere with 
normal breathing (Turgeon and Meloche, 2009). Wnt7b promotes mesenchymal 
proliferation and supports vascular development in the lung. Wnt7b deficient mice die 
within 10 minutes of being born and their small and collapsed lungs exhibit vascular 
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defects that results in vessel rupture and hemorrhage at birth (Shu et al., 2002). Another 
important regulator of the lung mesenchyme is Fgf9, in the absence of which, mice 
display reduced branching complexity that leads to abnormally small lungs, and this 
results in neonatal lethality in these mice (Colvin et al., 2001). In contrast, Asap1 
mutants do not exhibit collapsed, hemorrhagic lungs. Rather, functional analyses 
revealed differences in lung aeration areas, with Asap1GT/GT lungs displaying many 
areas of thick mesh-like parenchyma as opposed to the well-aerated parenchyma in 
Asap1+/+ lungs.  
 
Surfactant production and clearance of the liquid from the lung are required to attain 
normal respiration after birth. Failure to achieve this could lead to neonatal death shortly 
after birth and respiratory distress in the living pups, similar to the phenotype observed 
in Asap1 mutant mice. Surfactant protein B coding gene Sftpb deletion results in 
production of aberrant surfactant lipids that disrupt lung inflation, leading to cyanosis 
and death of pups within a few minutes (Clark et al., 1995). Further studies on 
understanding bradypnea in Asap1GT/GT pups could benefit from exploring whether 
absence of Asap1 affects biosynthesis of surfactants.  
 
A number of non-cell-autonomous factors could also conceivably affect breathing in 
Asap1GT/GT pups, and these may include endocrinal defects that affect lung 
development. Corticotropin-releasing hormone (CRH) deficient mice show dependency 
on glucocorticoid for lung maturation in fetal lungs. CRH deficient mice grow up 
normally and are fertile, with no overt phenotype, indicating a role of glucocorticoids 
during fetal rather than postnatal life (Muglia et al., 1995). Prostaglandins have been 
shown to be important players in the closure of ductus arteriosus, required for the 
transition from the fetal (placental) circulation to respiratory circulation (increased blood 
flow to the lung). Accordingly, mice deficient in prostaglandin E2 receptor gene die 
between 24-48 hours after birth due to lung edema and congestive heart failure (Segi et 
al., 1998). Kif1b deficient mice that no longer have the ability to produce a microtubule 
motor protein necessary for axonal transport, die due to failure in lung expansion (Zhao 
et al., 2001). Targeted deletion of muscle regulatory factor myogenin is responsible for 
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cyanosis and death in neonates arising due to insufficient respiration from a defective 
diaphragm (Nabeshima et al., 1993). It will therefore be interesting in future work to 
explore whether these factors play a role in the breathing defect observed in ASAP1 
deficient mice 
 
4.1.2 Ossification defects 
 
Through careful perinatal analysis, it was revealed that Asap1GT/GT embryos and 
neonates both exhibited significantly smaller sizes and weights as compared to their 
wildtype counterparts. This stunted growth in the absence of Asap1 may be critical for 
breathing and overall survival of Asap1GT/GT neonates. The skeleton spans throughout 
the body, and is comprised of two distinct tissues, cartilage and bone (Karsenty and 
Wagner, 2002). Osteogenesis encompasses two major processes of bone formation, 
namely intramembranous and endochondral ossification, both involving transformation 
of pre-existing mesenchymal tissue into bone tissue. Intramembranous ossification 
occurs when the pre-existing mesenchymal tissue converts directly into bone, like the 
bones of the skull. The other mode of bone formation, known as endochondral 
ossification occurs when the mesenchymal tissue is converted into cartilage and then to 
bone, like all the bones in the body other than those of skull and clavicle (Gilbert, 2000). 
Asap1GT/GT embryos display defective ossification, and interestingly, the absence of 
Asap1 results in defects in both intramembranous as well as endochondral ossification. 
Such defects may work to predispose the growing embryo to growth retardation, in the 
absence of Asap1. Mice deficient for Runx2 die shortly after birth due to lack of 
breathing. Maturational arrest of osteoblasts in these mice leads to complete blockage 
of intramembranous and endochondral ossification (Komori et al., 1997). Abnormal 
respiration could also result from either a complete absence or a smaller rib cage 
associated with inefficient lung inflation, as seen in Myf5 knockout mice and Tbx18 null 
mice, respectively (Braun et al., 1992; Bussen et al., 2004). Asap1GT/GT neonates have 
a developed rib cage, ribs and sternum, however size of the thoracic cavity remains to 
be studied in these pups.  
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Many chromosomes harbor regions that contain clusters of genes that may have similar 
functions, and mutations in these regions often lead to similar disease phenotypes. It is 
interesting to note that chromosome 8 contains at least two distinct gene clusters – 
genes involved in epilepsies, on the long arm, and presumptive tumor suppressor genes 
on the short arm. There are some genes present in proximity to Asap1 that may be of 
interest. These include CCAL1 (chondrocalcinosis) at 8q, NBS1 (Nijmegen breakage 
syndrome 1) at 8q21, and PLEC1 (plectin 1) and TNFRSF11B (tumor necrosis factor 
receptor superfamily 11b) both at 8q24. Mutations in these genes lead to abnormalities 
of the bone and muscle, for example, CCAL1 is implicated in chondrocalcinosis with 
early-onset osteoarthritis, NBS results in growth retardation, immunodeficiency and 
predisposition to cancers, PLEC1 mutations are associated with muscular dystrophy, 
and mutated TNFRSF11B causes juvenile Paget’s disease that affects bone growth 
(Carney et al., 1998; Hilton and Wells, 2001). It is not unprecedented that targeted 
mouse mutations may result in up- or down- regulation of neighboring genes (West et 
al., 2016). In the case of Asap1, such mutations in the neighboring gene may produce 
phenotypes that exhibit growth retardation, muscular dystrophy or bone defects. This is 
however unlikely, given the strong phenotype that correlates well with the absence of 
Asap1.  
 
The regulation of the process of cartilage formation is crucial to embryonic bone 
development and postnatal bone growth. Upon exiting from the cell cycle, hypertrophic 
chondrocytes undergo apoptosis so as to be replaced by bone (Ye et al., 2005). In the 
context of chondrocytes, the absence of Asap1 may orchestrate generation of 
multinucleate cells following cytokinesis failure, which may lead to increased apoptosis. 
In Drosophila, Asap regulates cleavage furrow biosynthesis by recycling Arf1 to the 
Golgi from post-Golgi membranes thereby organizing Golgi and providing optimal Golgi 
output (Rodrigues et al., 2016). Upon cytokinesis failure, cells either undergo apoptosis 
or cell cycle arrest and senescence, and the presence of multinucleate cells positively 
correlates with apoptosis (Mason and Bessler, 2011). Thus the absence of Asap1 in the 
Asap-Arf1-Golgi pathway for biosynthesis of cleavage furrow may orchestrate the 
generation of multinucleate cells following cytokinesis failure, which may lead to 
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increased apoptosis. Could then, the delayed ossification as observed in Asap1GT/GT 
embryos correspond to specific time points where increased chondrocyte apoptosis 
does not match with osteoblast formation? In view of this possibility it would be 
worthwhile to explore the status of expression of various apoptotic genes such as 
caspases, Bcl-2 etc., in Asap1GT/GT embryonic cells to understand further the defective 
ossification phenotype of Asap1GT/GT embryos.  
 
The literature does not provide evidence of in vivo chondrocyte motility as yet, and 
chondrocyte migration has been so far studied only in in vitro model systems. It has 
however, been established that these cells possess a primary cilium, in addition to other 
finger-like processes. The primary cilium has been proposed to be involved in 
mechanotransduction (McGlashan et al., 2008). The primary cilia have been 
demonstrated to be critical for endochondral bone formation during limb development 
(Haycraft et al., 2007). It is known that ASAP1 is an important scaffold protein that links 
Arf4 to the Rab GTPases involved in the ciliiogenesis cascade (Wang et al., 2012). 
ASAP1 controls cargo progression and the direction of ciliary traffic and may also 
control actin polymerization in the periciliary region so as to facilitate ciliary trafficking 
(Wang and Deretic, 2015). It is reasonable to argue that loss of Asap1 may lead to 
defective cilia formation, restricting chondrocyte movement within the matrix of cartilage, 
and hence affecting cartilage development as observed in Asap1GT/GT embryos. 
 
4.1.3 The transient nature of the Asap1GT/GT phenotype 
 
Bradypnea and growth retardation are prominent phenotypes of Asap1GT/GT neonates at 
P0. However, these differences between Asap1+/+ and Asap1GT/GT embryos last for only 
the initial 24 hours after birth. These differences gradually diminish over the next few 
days, and pups belonging to both genotypes display comparable values for breathing 
rates and growth. These data show that Asap1 is largely dispensable for mouse 
embryonic development. The transient nature of the physiological phenotype associated 
with loss of Asap1 may be attributed to a genetic or functional compensation 
mechanism. Paralogous gene redundancy is often regarded as a mechanism for lack of 
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a knockout phenotype. Two genes, MyoD and Myf5 that are implicated in skeletal 
muscle development, do not have an overt phenotype when either of them are knocked 
out. However, mice deficient for both these genes are completely devoid of skeletal 
muscle (Rudnicki et al., 1993). MyoD-null mice show delayed limb and brachial arch 
muscle development, and Myf5-null mice have abnormal rib development, and thus 
these two genes display partial redundancy (Kablar et al., 1997). There also exists a 
possibility of an unequal genetic redundancy in paralogous genes, as in the case of 
knockout mice of various caspases. Casp8 and Casp9 knockout result in pre- and 
perinatal lethality, respectively whereas knockout mice of Casp1 and Casp12 have no 
detectable phenotype (Barbaric et al., 2007; Kuida et al., 1995, 1998; Varfolomeev et 
al., 1998). It is imperative that gene expression profiling be conducted on Asap1GT/GT 
embryos as it will enable identification of genes performing similar functions or genes 
belonging to signaling pathways of similar processes as regulated by Asap1. This could 
potentially lead to identification of new, previously undescribed phenotype in multiple 
gene knockout mice involving Asap1 deletion, and thus divulge novel roles of this gene.  
 
Previous studies on the other two members of ASAP family, namely ASAP2 and 
ASAP3, do not report their cellular expression pattern. Future work will describe 
tissue/organ-specific expression of ASAP1 isoforms to answer the intriguing question of 
whether functional diversity exists within the ASAP family. The present study provides 
the first look at the global pattern of ASAP1 expression in mouse tissue. With this 
knowledge, it is now possible to focus on specific physiological processes that may be 
regulated by ASAP1 and its isoforms, either in combination or independently. There is 
also a possibility that a shift in the expression of isoforms occurs during embryonic 
development, and this may also be revealed by studies on mice harboring deletion of 
these isoforms. It has previously been reported that two ARF-GAP GIT family members, 
GIT1 and GIT2 display differential expression in mice tissue. Mice deficient for GIT1 and 
GIT2 show a broad distribution of GIT2, whereas GIT1 expression was found to be 
restricted to certain cell populations. A developmental shift in the expression of these 
genes occurs in testis, where GIT2 is expressed by spermatogonia and mature 
spermatids express GIT1 (Schmalzigaug et al., 2007). Studies exploring expression 
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pattern of ASAP1 isoforms in the Asap1 knockout mouse model generated in our lab, 
coupled with studies on individually knocked out Asap2 and Asap3 will contribute 
immensely to our current understanding of the role of Asap1 in embryonic development.  
 
4.2 Does Asap1 affect angiogenesis? 
 
The developing embryo engages in many physiological events at different stages of 
gestation. Certain critical physiological processes prepare the embryo for its post-
partum life, like angiogenesis (Adams and Alitalo, 2007). In mice, intraretinal 
vasculature development takes place postnatally, in a distinct spatiotemporal manner 
that can be monitored (Dorrell and Friedlander, 2006). This development is strain-
specific and varies within a margin of a few days for different strains of mice (Stahl et 
al., 2010). I used the FVB strain of mice in my studies. The most commonly utilized 
mouse strain to study the time course of normal vascular development is C57Bl/6 mice, 
and in these mice vessels grow radially from the optic nerve into the periphery seven 
days after birth, thus forming the superficial vascular plexus. Vertical outgrowth of 
superficial capillaries forms at first the deep plexus and then the intermediate vascular 
plexus after eight post-natal days. After about 12 days of birth, the deep plexus grows 
and reaches retinal periphery, followed shortly by the intermediate plexus. It takes 
approximately three weeks after birth for all the three vascular layers to completely 
develop and for the many vessels between these layers to interconnect them (Stahl et 
al., 2010). One of the major regulators of blood vessel formation and function is VEGF. 
Specialized endothelial cells present at the tips of vascular sprouts respond to VEGF 
regulated angiogenic sprouting by guided migration (Gerhardt et al., 2003). Endothelial 
cells express high levels of ASAP1, which has been shown to be a part of a signaling 
cascade employed for angiogenesis activities. The GEP100-Arf6-ASAP1-cortactin 
pathway is activated by VEGFR2 (Hashimoto et al., 2011). It is known from the present 
study, and also from other research groups, that ASAP1 is involved in regulating cellular 
motility. Fibroblasts deficient in ASAP1 exhibit significantly reduced motility, as is 
evident from wound healing assay performed on embryonic fibroblasts obtained from 
Asap1+/+ and Asap1GT/GT mice. Taking into account the expression of ASAP1 in 
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endothelial cells and its role in cellular motility, a presumptive role of ASAP1 in 
angiogenesis emerges. The hypothesis that absence of ASAP1 in the retinas of 
Asap1GT/GT mice may lead to a delay in the outgrowth of retinal vasculature, was tested 
by staining retinas of Asap1+/+ and Asap1GT/GT pups isolated at various post-natal days. 
Retinal angiogenesis was observed to be reduced in P3-P5 Asap1GT/GT retinas as 
compared to Asap1+/+ retinas. At P7 retinas from both Asap1+/+ and Asap1GT/GT mice 
showed comparable angiogenesis. The number of animals at P3 and P5 were not 
sufficient to make a statistically significant argument, although a trend is evident. So that 
the involvement of ASAP1 in retinal angiogenesis can be underscored, it is highly 
desirable that this study is conducted on a larger cohort of animals and statistically 
robust data is obtained.  
 
The shared radial orientation of blood vessels and ganglion cell axons and the precise 
alignment of planar capillary plexuses with horizontal neural and astrocytic laminae, 
point towards an association between retinal vascular structures and neural structures 
(Gariano and Gardner, 2005).  Astrocyte precursors enter the retina via the optic nerve 
and radiate towards the periphery to form an astrocytic meshwork that serves as a 
template for subsequent vascularization. Endothelial cell present at the tip of the 
growing retinal vessel extend along the processes of the underlying glial cells (Dorrell et 
al., 2002). In the case of Asap1GT/GT mice that display an initial delayed retinal vascular 
outgrowth, it will be interesting to investigate if the glial outgrowth also exhibits a similar 
phenotype and if so, can that be accounted for the delayed retinal angiogenesis in these 
mice.  
 
Angiogenesis is important in bone morphogenesis. During endochondral ossification, 
bone replaces avascular cartilage. Blood vessel invasion is required for formation of 
secondary ossification centers and subsequent bone formation (Gerber and Ferrara, 
2000). The delayed ossification seen in Asap1GT/GT mice could possibly be attributed to 
delayed angiogenesis in them. To confirm this, blood vessel invasion in the epiphyses 
of Asap1GT/GT mice should be checked.  
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The various possible inter-regulation that exists among different physiological systems, 
that may work together to lead to the mouse phenotype in the absence of Asap1 is 
presented along with the important findings from Asap1GT/GT mice (Figure 30, Figure 
31).  
 
 
 
Figure 30. Physiological systems regulating Asap1 knockout mouse phenotype. 
Schematic of multiple physiological systems that work together to dictate the mouse phenotype 
in the absence of Asap1. Asap1GT/GT mice are fed and nursed normally and they display normal 
suckling and skin hydration (indicated in green boxes). They however, show defective 
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ossification, bradypnea and severe growth retardation and delayed angiogenesis (indicated in 
yellow boxes). The physiological systems that may regulate these phenotypes are shown.  
 
 
 
 
 
 
Figure 31. Notable findings from the Asap1GT/GT mice. 
Schematic highlighting the most important findings from Asap1GT/GT mice at various stages of 
gestation to adulthood. The transient delayed phenotype of reduced breathing and growth 
defects, along with defective ossification and delayed angiogenesis is observed in the 
Asap1GT/GT neonates. These physiological functions are restored in the adult Asap1GT/GT mice. 
 
 
4.3 How does Asap1 affect breast tumor development and metastasis? 
 
PyMT Asap1+/+ and PyMT Asap1GT/GT mice presented with multifocal mammary tumors, 
with PyMT Asap1GT/GT mice displaying an early onset of tumor formation, evident in their 
shorter tumor-free survival. The higher tumor burden in PyMT Asap1GT/GT mice in the 
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weeks immediately before their sacrifice indicated that the absence of Asap1 in the 
PyMT transgenic mice led to accelerated and more aggressive tumor growth. Lungs of 
PyMT Asap1GT/GT mice exhibited higher numbers and larger metastatic foci. 
  
To understand the phenotype of tumors developed in the Asap1GT/GT background in 
PyMT-driven breast tumors, tumor cells were isolated, and critical cellular processes 
were studied. It is known that ASAP1, via its GAP activity, enhances general motility of 
cells (Furman et al., 2002). Fibroblasts from Asap1+/+ and Asap1GT/GT mice were also 
isolated and used as positive controls to study cellular migration in PyMT Asap1+/+ and 
PyMT Asap1GT/GT tumor cells. Whereas Asap1GT/GT fibroblasts displayed significantly 
reduced motility in comparison to Asap1+/+ fibroblasts, PyMT Asap1GT/GT cells showed 
no differences in motility behavior as compared to PyMT Asap1+/+ cells. Thus the ability 
of ASAP1 to regulate motility appears to be cell type dependent. ASAP1 clearly 
regulates the motility of fibroblasts, but its loss did not affect the motility of the breast 
cancer cells.  
 
Cell migration is a multi-step process that requires coordinated effects of formation of 
new adhesions at the leading edge and breaking of adhesions at the trailing edge of a 
cell. Such processes involve extensive cytoskeletal remodeling in which ASAP1 plays a 
role (Kassis et al., 2001; Lambrechts et al., 2004). Cell spreading assays were 
performed to assess changes in actin cytoskeleton and understand the reduced 
migration phenotype of Asap1GT/GT fibroblasts, and also to explore if any adhesion 
defects existed in PyMT Asap1+/+ and PyMT Asap1GT/GT cells. Asap1GT/GT fibroblasts 
exhibited prominent attachment defects as compared to Asap1+/+ fibroblasts. Tumor 
cells obtained from PyMT Asap1+/+ and PyMT Asap1GT/GT mice showed no differences 
in attachment to fibronectin-coated plates. When fibroblasts and tumor cells of both 
genotypes were stained for actin, to check whether inefficient actin remodeling was 
responsible for migration and adhesion defects, it was found that the cells did not show 
any differences in their actin expression. Taken together, these data suggest that the 
ability of ASAP1 to stimulate metastasis formation by tumor cells may not be connected 
to its role in regulating motility. 
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Upon a migratory stimulus, Asap1+/+ fibroblasts showed a strong, transient nuclear actin 
expression that could possibly reflect cytoskeletal remodeling, absent in Asap1GT/GT 
fibroblasts. Nuclear actin is known to negatively regulate key cytoskeletal and adhesion 
genes and thus inhibit migration, and exclusion of actin from the nucleus has been 
shown to enhance cell migration (Sharili et al., 2016). Since the nuclear actin 
expression observed in Asap1+/+ fibroblasts was a transient effect, lasting between 20-
50 minutes of EGF addition, it is plausible that this does not affect overall cell motility as 
assessed in a period of 24 hours.  
 
Early tumor onset in PyMT Asap1GT/GT mice may be paralleled by early metastasis 
formation. It would therefore be worthwhile to study the lungs of these mice a few weeks 
earlier than when the mice were sacrificed in my study. PyMT Asap1GT/GT mice show 
significantly higher tumor burden in weeks 10, 11 and 12, after first palpable tumors 
develop in them. In the absence of any migration and adhesion defects in PyMT 
Asap1GT/GT cells as compared to PyMT Asap1+/+ cells, it would be interesting to find out 
whether tumor cells isolated from earlier stages of tumor development exhibit 
differences in motility and adhesion.  
 
The question that arises from these observations is – how do PyMT Asap1GT/GT mice 
display enhanced metastatic potential when PyMT Asap1GT/GT cells do not exhibit 
features of highly motile cells that are capable of increased metastasis formation? There 
can be two possible explanations for this. One, Asap1 has recently been shown to 
regulate mammary progenitor cells. In primary mouse mammary stem cells, Asap1 
knockdown resulted in an increased repopulating frequency of these cells, indicating 
that Asap1 negatively regulates either mammary stem cell activity or number (Sheridan 
et al., 2015). Previous studies have demonstrated that cancer stem cells may exist in 
human breast cancer (Al-Hajj et al., 2003). To confirm whether this is the case, tumors 
and metastasis-bearing lungs from PyMT Asap1+/+ and PyMT Asap1GT/GT mice can be 
stained with established progenitor/stem cell markers like BCRP-1 (breast cancer 
resistance protein-1) and Sca-1 (stem cell antigen-1).  
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The second possible answer to the above mentioned question could be that this effect 
may not be entirely tumor cell-autonomous. The involvement of stroma in cancer 
progression and metastasis has been extensively studied. Many studies report active 
contribution of stroma in cancer progression, and there are also studies that highlight 
how the microenvironment of a tumor acts to restrict its growth (Özdemir et al., 2014; 
Rhim et al., 2014). Normal murine fibroblasts have been shown to restrain the growth of 
transformed baby hamster kidney cells (Stoker et al., 1966). It is possible that deletion 
of Asap1 results in the disruption of certain stromal components that are no longer able 
to exercise restrictive control on tumor growth and metastasis in PyMT Asap1GT/GT mice, 
thus leading to faster, more aggressive tumors that bear enhanced metastatic potential. 
Asap1 knockout mice used in this study bear global deletion of the gene. Hence, to 
understand the role of stroma in tumor progression in these mice it is required that 
PyMT Asap1GT/GT tumors be transplanted in a wild-type background, and PyMT 
Asap1+/+ tumors transplanted in PyMT Asap1GT/GT mice. Tumor development and 
metastasis formation arising from these transplanted tumors would divulge important 
information as to the involvement of stromal compartment in breast tumor progression in 
the absence of Asap1.  
 
The notion that ASAP1 expression and function in stromal cells may be decisive for the 
tumor development and metastasis is supported by the observation that compared to 
PyMT Asap1+/+ tumors, PyMT Asap1GT/GT tumors displayed a very strong a-SMA 
expression, highlighting the presence of a reactive stroma. Peritumoral stromal cells in 
breast cancer express a-SMA, and its expression can be used as a surrogate marker 
for the presence of a reactive stroma. Resident normal fibroblasts, in a reactive tissue, 
convert into a-SMA expressing myofibroblasts, and the cells closest in proximity to 
tumor cells show strongest conversion. This is explainable by a concentration gradient 
of growth factors, like transforming growth factor-b (TGF-b), originating from the tumor 
cells (Rønnov-Jessen et al., 1995). Future experiments that would aim to quantify the 
stromal contribution in PyMT Asap1+/+ and PyMT Asap1GT/GT tumors, by way of 
establishing a reactive stroma index, would add to the understanding the role of stroma 
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in tumor progression in these mice. Reactive stroma index would assess stromal 
percentage to tumor mass.  
 
Other data suggest that ASAP1 in tumor cells themselves plays a decisive role in 
determining tumor growth and dissemination. Thus, ectopic expression of ASAP1 in 
pancreatic carcinoma cells sufficed to promote their metastasis in vivo (Müller et al., 
2010). Furthermore, I also studied the effect of Asap1 on Neu- and Wnt- driven 
tumorigenesis. Both Neu- and Wnt- driven tumors in Asap1+/+ and Asap1GT/GT mice 
displayed long and highly variable latency periods in tumor formation and a complete 
lack of observable metastases in the lungs. However, no difference was observed 
between wildtype and Asap1GT/GT mice. As ASAP1 was also lacking in the stroma of 
these tumors in the same way as in the PyMT model, this suggests a decisive role for 
ASAP1 in the PyMT tumor cells themselves, rather than a purely stromal defect as a 
consequence of ASAP1 deficiency. Taken together, these observations suggest that 
ASAP1 likely plays important roles in both the tumor cells themselves and in the stromal 
cells of the tumor, and that the differences in tumor development and metastasis 
observed in PyMT Asap1+/+ and PyMT Asap1GT/GT is probably due to a combination of 
these effects. 
 
Breast cancer is a heterogeneous disease comprising various subtypes. It has been 
previously argued that the subtypes depend on the oncogene and the cell of origin 
being transformed, hence MMTV-PyMT tumors have been shown to resemble luminal 
subtype of human breast cancer since MMTV promoter is known to be active in luminal 
epithelial cells (Vargo-Gogola and Rosen, 2007; Wagner et al., 2001; William Petersen 
et al., 2001). PyMT Asap1+/+ and PyMT Asap1GT/GT tumors express CK18, which is a 
luminal marker, and interestingly, they also express CK14, a basal marker. Such a 
concomitant expression of luminal and basal markers has been earlier reported in a 
luminal breast cancer model that employs MMTV to drive oncogenic expression of 
mutant PIK3CA H1047R leading to the formation of tumors that recapitulate 
heterogeneity of human tumors (Meyer et al., 2011). Recent studies demonstrate that 
both subtypes of breast cancer arise from the luminal epithelial lineage, and so as to 
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become malignant, differentiated luminal cells must acquire basal-like traits (Horwitz et 
al., 2008; Lim et al., 2009; Molyneux et al., 2010). Although PyMT Asap1+/+ and PyMT 
Asap1GT/GT tumors co-express luminal and basal cytokeratins, PyMT Asap1GT/GT tumors 
exhibit a stronger CK14 expression. This may possibly reveal the plasticity in the 
luminal compartment of PyMT Asap1GT/GT tumors that is responsible for recapitulating 
the heterogeneity observed in human breast tumors.  
 
To understand how closely ASAP1 might be involved in breast tumor progression in 
PyMT-driven mouse models, mammary glands of PyMT Asap1+/+ mice at specific time 
points during tumor growth can be stained for ASAP1 expression and compared. This 
spatio-temporal expression analysis of PyMT Asap1+/+ mammary glands can reveal 
hyperplasia-associated changes in the breast and whether ASAP1 regulates any stage-
specific aspect of breast tumor progression. Since elevated expression of ASAP1 in 
various cancer entities has been strongly evidenced, it is desirable that tumors and 
lungs obtained from PyMT Asap1+/+ mice be assessed for ASAP1 expression. It will 
reveal whether primary and metastatic tumors obtained from spontaneous murine 
mammary models reflect the observations made in the clinics with respect to ASAP1 
expression. The importance of finding out breast cancer subtypes in which ASAP1 
expression is clinically relevant is revealed by a retrospective study that analyzed 479 
patients treated with breast conservation therapy (BCT). Out of these, 20 patients 
developed local recurrence, and clinicopathological factors like margin-status, node-
positivity and hormone receptor-status did not correlate with the rapidity of recurrence 
whereas concomitant expression of ASAP1 and GEP100 significantly associated with 
the rapidity (Kinoshita et al., 2013). Neither the individual expression of ASAP1 and 
GEP100, nor the individual status of ER and PR showed any statistical significance for 
the rapidity of recurrence. Moreover, owing to a small sample size, this study was 
unable to establish whether simultaneous expression of ER, PR, HER2, ASAP1 and 
GEP100, could correlate with local recurrence. Under these circumstances, it is 
imperative that human breast tumors are stratified on the basis of different subtypes and 
the relevance of ASAP1 expression in each of the subtype be determined.  
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4.4 Conclusion 
 
This is the first study that has examined the involvement of ASAP1 in murine embryonic 
development, normal physiology and breast tumor metastasis in autochthonous models 
harboring global deletion of Asap1. Key findings are (i) the observed transient reduction 
in the expected number of homozygous knockout offspring at birth, likely caused by 
growth retardation and respiratory distress in the Asap1GT/GT pups; (ii) MMTV-PyMT 
Asap1GT/GT mice have an earlier tumor onset, faster tumor growth and increased 
metastasis to the lungs, in contrast to previous cell line-based studies, which together 
with other observations suggests that ASAP1 exerts both tumor cell autonomous and 
non-autonomous effects; (iii) While fibroblasts taken from Asap1+/+ and Asap1GT/GT mice 
showed marked differences in motility and adhesion, no such differences were 
observed in Asap1+/+ and Asap1GT/GT breast cancer cells. Future work will focus on 
understanding in more detail how ASAP1 regulates tumor growth and metastasis. 
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